Phase I Clinical Trial of HSV G207 Alone or With a Single Radiation Dose in Children With Recurrent Supratentorial Brain Tumors
Phase: PHASE1
Conditions: Supratentorial Neoplasms, Malignant, Malignant Glioma, Glioblastoma, Anaplastic Astrocytoma, PNET, Cerebral Primitive Neuroectodermal Tumor, Embryonal Tumor
Sponsor: Gregory K. Friedman, MD

UAB Protocol #:  1472   
Version 04.20.2020 
Page 1 
 Phase 1 Clinical Trial of HSV G207 Alone or with a Single Radiation Dose in 
Children with Recurrent Supratentorial Brain Tumors 
 
IND No.: 
IND 16294, approved January 14, 2015 
 
 
Site: 
University of Alabama at Birmingham  
Principal Investigator: 
Gregory K. Friedman, M.D., Dept. of Pediatrics, 
Hematology/Oncology 
 
Co-Investigators: 
James M. Johnston Jr, M.D., Dept. of Surgery, Div. of Neurosurgery
James M. Markert, M.D., Dept. of Neurosurgery    
John Fiveash, M.D., Dept. of Radiation Oncology 
Asim K. Bag, M.D., Dept. of Radiology, St. Jude Research 
Hospital 
Elizabeth Alva, M.D., Dept. of Pediatrics, Hematology/Oncology 
Avi Madan-Swain, Ph.D., Dept. of Pediatrics, Hem./Oncology 
 
 
 
 
 
Medical Monitors:             Clinical Trials Review Committee 
   Tony McGrath, M.D., Dept. of Pediatrics 
                                             Shannon Ross, M.D., Dept. of Pediatrics 
 
 
 
 

UAB Protocol #:  1472   
Version 04.20.2020 
Page 2 
Table of Contents 
 
 
Synopsis .........................................................................................................................5 
1.0 
Introduction ..................................................................................................................8 
2.0 
Background and Rationale .........................................................................................8 
2.1 Disease Processes Involved in Malignant Brain Tumors .....................................8 
2.2 Neoplastic Therapy Using the HSV Virus ............................................................8 
2.3 Development of G207 and Preclinical Studies .....................................................9 
2.4 Genetically Engineered HSV-1 and Radiation ...................................................10 
2.5 Previous Clinical Experience ..............................................................................11 
2.6 Safety Information ..............................................................................................12 
3.0 
Study Objectives.........................................................................................................13 
3.1 Primary Objective ...............................................................................................13 
3.2 Secondary Objective ...........................................................................................13 
4.0 
Study Design ...............................................................................................................13 
4.1 Overview .............................................................................................................13 
4.2 Sample Size Considerations................................................................................14 
4.3 Statistical Considerations……………………….…………………………...….15 
4.4 Treatment Summary ...........................................................................................15 
4.5 Stopping Rules………………………………………………………………….16 
4.6 Data and Safety Monitoring ................................................................................16 
5.0 
Study Population ........................................................................................................16 
5.1 Inclusion Criteria ................................................................................................16 
5.2 Exclusion Criteria ...............................................................................................17 
6.0 
Study Methods and Procedures ................................................................................17 
6.1 Designated Laboratories .................................................................................... 17 
6.2 Screening Evaluations.........................................................................................18 
6.3 Intratumoral Inoculation with G207……………………………………………18 
6.4 Patient Management Following Virus Infusion ..................................................19 
6.5 Radiation Planning and Treatment .....................................................................21 
6.6 Supportive Care Guidelines ................................................................................22 
6.7 Study Evaluations by Time Point .......................................................................23 

UAB Protocol #:  1472   
Version 04.20.2020 
Page 3 
7.0 
Study Test Article ..................................................................................................... 25 
7.1 Investigational Product Designation ...................................................................25 
7.2 Dose ....................................................................................................................25 
7.3 Precautions in Handling and Disposal ............................................................... 25 
8.0 
Study Conduct ............................................................................................................26 
8.1 Clinical Events: Adverse Medical Experiences and Concurrent Illnesses .........26 
8.2 Reporting of Clinical Events .............................................................................. 28 
8.3 Reporting of Serious Life-Threatening Adverse Events .................................... 28 
8.4 Declaration of Treatment Failure ........................................................................28 
8.5 Insurance and Indemnity .....................................................................................28 
8.6 Protocol Deviations ............................................................................................ 28 
8.7 Data and Safety Monitoring Plan ....................................................................... 28 
8.8 Retention of Records.......................................................................................... 29 
9.0 
Study Analysis ........................................................................................................... 29 
9.1 Analysis of Safety .............................................................................................. 29 
9.2 Clinical Response................................................................................................30 
References……………………………………………………………………...……32 
 
 

UAB Protocol #:  1472   
Version 04.20.2020 
Page 4 
Appendices 
Appendix A 
Patient Study Schedule ...................................................................................... i 
 
                  Appendix B 
Modified Lansky/Karnofsky Status Determination .......................................... ii 
                  Appendix C                         
                       Preparation of G207 .......................................................................................... iii 
                  Appendix D                         
                       MRI Sequences ...................................................................................................v 
 
 

UAB Protocol #:  1472   
Version 04.20.2020 
Page 5 
Study Synopsis 
 
Title of Study: 
Phase 1 Clinical Trial of HSV G207 Alone or With a Single 
Radiation Dose in Children with Recurrent Supratentorial Brain 
Tumors 
Principal Investigator: 
Gregory 
K. 
Friedman, 
M.D., 
Dept. 
of 
Pediatrics, 
Hematology/Oncology 
Co-Investigators: 
James M. Johnston Jr, M.D., Dept. Neurosurgery 
James M. Markert, M.D., Dept. of Neurosurgery 
John Fiveash, M.D., Dept. of Radiation Oncology 
Asim K. Bag, M.D., Dept. of Radiology, St. Jude Research 
Hospital 
Elizabeth Alva, M.D., Dept. of Pediatrics, Hematology/Oncology 
Avi Madan-Swain, Ph.D., Dept. of Pediatrics, Hem./Oncology 
Medical Monitors: 
Clinical Trials Review Committee 
Tony McGrath, M.D., Dept. of Pediatrics 
 
Shannon Ross, M.D., Dept. of Pediatrics 
Study Center: 
University of Alabama at Birmingham 
 
Children’s of Alabama  
Clinical Phase: 
Phase 1 (open-label) 
Study Rationale: 
Outcomes for children with recurrent supratentorial brain tumors are 
extremely poor 
Study Objectives: 
Primary: To assess the safety and tolerability of G207 administered 
intratumorally via controlled rate alone or followed by a single dose 
of radiation within 24 hours of G207 administration in children with 
recurrent or progressive malignant supratentorial brain tumors. To 
establish a maximum tolerated dose (MTD) or maximal planned 
dose if no dose-limiting toxicity is observed. 
 
Secondary: To obtain preliminary information concerning the 
potential efficacy of and biological response to G207 alone or 
combined with a single dose of radiation in pediatric patients with 
recurrent or progressive malignant brain tumors by assessing 
radiographic response, performance scale, progression-free and 
overall survival, immune response, and presence of G207 in blood, 
saliva, and conjunctiva. 
Investigational Drug: 
G207 is a genetically altered herpes simplex virus that has been 
demonstrated to be aneurovirulent secondary to deletions of both 
copies of the γ134.5 gene. After stereotactic biopsy to confirm tumor 
recurrence, up to 4 silastic catheters will be passed to predefined 

UAB Protocol #:  1472   
Version 04.20.2020 
Page 6 
coordinates of enhancing tumor, if present.  Catheters may be placed 
in non-enhancing regions if residual tumor is confirmed in those 
locations. Subsequently, patients will be inoculated with 2.4 ml of 
G207 over 6 hours alone or followed by a single 5 Gy fraction of 
radiation within 24 hours of virus inoculation.  
Subject Population: 
Up to 24 pediatric patients, ages 3 to 18 years, with 
recurrent/progressive malignant supratentorial brain tumors will be 
enrolled in this study. 
Treatment Indication: 
Progressive or recurrent growth of malignant supratentorial brain 
tumor after initial surgery, radiotherapy, and/or chemotherapy.  
Patients with brainstem, cerebellar or intraventricular tumors will 
not be eligible. 
Study Design: 
This study will be a Phase 1, open-label study of HSV G207 to 
assess its safety and tolerability. A traditional 3 + 3 design will be 
used. The following dose escalation scheme will be used: 
Dose Level 
Patients 
Dose (pfu) 
Volume 
# Loci 
-1 
3 
1x106 
2.4 ml 
1-4 
1 
3 (+3) 
1x107 
2.4 ml 
1-4 
2 
3 (+3) 
1x108 
2.4 ml 
1-4 
3 
3 (+3) 
1x107 + 5 Gy radiation 
2.4 ml 
1-4 
4 
3 (+3) 
1x108 + 5 Gy radiation 
2.4 ml 
1-4 
 
The first three patients enrolled will be entered at the starting dose 
(dose level 1). If no significant toxicities are encountered, 
subsequent doses will be escalated as outlined above. If significant 
toxicity is encountered in one patient at the starting dose, 3 
additional patients will be treated at that dose.  If two or more 
patients have toxicity at the starting dose, a cohort will be added at 
1 x 106 plaque-forming units (pfu) (dose level -1).  If two or more 
patients have toxicity at this dose, the study will be terminated.  
Three additional patients may be added at any dose level if toxicity 
in one patient is observed.  If toxicity in a second patient is observed 
at any dose level, no further patients will receive that dose level, and 
the dose immediately below will be declared the maximally 
tolerated dose (MTD). There will be a minimum 28 day observation 
period between the first and second patient in each cohort and a 28 
day observation period from one cohort to the next to allow for 
evaluation of potential toxicity.  It will take an estimated 24-30 
months to complete patient accrual. 
Safety Analysis: 
Patient monitoring will be appropriately tapered from the initial 
intensive monitoring in the Pediatric Intensive Care Unit 
immediately after biopsy and catheter placement, to an inpatient 
room, and then to regular clinic follow-up visits.  In addition to 
regularly scheduled screening tests looking specifically for G207 
shedding and viremia, other routine evaluations will include vital 

UAB Protocol #:  1472   
Version 04.20.2020 
Page 7 
sign measurements, neurological exams, neurological performance 
scores, magnetic resonance imaging studies (MRIs), chemistry and 
hematology 
laboratories, 
urinalysis, 
and 
quality 
of 
life 
questionnaires (quality of life measures are optional consent). Two 
medical safety monitors, who have expertise in herpes encephalitis, 
will be integrally involved in the assessment of toxicity throughout 
the study. Safety/tolerability will be assessed by adverse events and 
laboratory tests. Descriptive statistics will be provided for selected 
demographic, safety data overall and by dose group. Additional 
exploratory analyses of the data will be conducted as deemed 
appropriate. 
Study Duration: 
Patients will have close scheduled follow up for 24 months     
following treatment with G207. Annual follow up appointments will 
be made for patients who survive longer than 24 months.  Patients 
whose tumor shows radiographic and clinical evidence of 
progression will be declared a treatment failure and may be 
considered as candidates for any other available therapy. 
Nonetheless, patients who have received G207 will continue long-
term follow-up even after receiving other cancer therapies.   
 
 
 

UAB Protocol #:  1472   
Version 04.20.2020 
Page 8 
1.0 Introduction: 
Primary CNS tumors are the most common solid neoplasm of childhood and the leading cause 
of cancer related death in pediatric patients. Approximately 25% of children with brain tumors will 
not be long-term survivors of their disease despite aggressive treatment with combinations of 
surgery, radiation, and chemotherapy.   Novel innovative treatments are greatly needed.  One 
promising new approach is the use of a genetically engineered, conditionally replicating herpes 
simplex virus (HSV) that has shown tumor specific tropism and potential efficacy in the treatment 
of malignant brain tumors. G207 is a genetically engineered HSV lacking genes essential for 
replication in normal brain cells. G207 has been shown to be efficacious in the treatment of both 
human and rodent tumors in murine models. Safety has been established following pre-clinical 
investigation involving intracranial inoculation in the highly HSV-sensitive owl monkey (Aotus 
nancymai). A Phase I study in adults with recurrent glioblastoma multiforme (GBM) demonstrated 
safety of intratumoral injections of G207 (1).  Patients in this study were treated with doses 
escalating from 1 x 106 pfu to 3 x 109 without serious adverse events or toxicity.  In a Phase Ib 
study in adults with recurrent GBM, patients were safely injected with two doses of the G207 
(totaling 1.15 x 109 pfu) pre- and post-tumor resection (2). A follow-up phase I trial of G207 given 
in combination with a single 5 Gy dose of radiation for recurrent GBM demonstrated safety and 
radiographic responses (3). A maximum tolerated dose was not reached in all 3 trials. 
2.0 Background and Rationale: 
2.1 Disease Processes Involved in Malignant Childhood Brain Tumors 
Central nervous system tumors are the most common solid neoplasm of childhood 
accounting for approximately 25% of all childhood malignancies and a leading cause of cancer 
related morbidity and mortality (4). Although survival rates for low-grade, localized tumors have 
improved, there remains a significant subset of patients with high-grade, unresectable and/or 
disseminated tumors that have very poor outcomes despite conventional treatment approaches 
including surgery, chemotherapy and radiation. For patients with high-grade recurrent tumors, 
traditional treatment usually only provides a brief interval of disease control (5,6). Furthermore, 
patients who survive their disease after traditional therapy often have long-term sequelae such as 
hormone dysfunction, neurosensory impairment, and neurocognitive changes that are attributed to 
the treatment (7-10).  
2.2 Neoplastic Therapy Using Genetically Engineered Herpes Simplex Virus 
Brain tumors are suitable targets for intervention using conditionally replicating viruses 
that replicate and kill tumor cells, while sparing the post-mitotic, non-dividing cell population of 
the brain. Many vectors have been considered for neoplastic therapy, including naked DNA, 
liposomes, and viruses. Attenuated HSV has a number of potential advantages as a neoplastic 
therapy for pediatric brain tumors. While traditional chemotherapy requires cancer cells to be 
dividing, HSV can enter a non-dividing cancer cell, replicate, and lyse the cell.  
HSV-1 is an enveloped, double-stranded DNA virus (11). It has a genome of approximately 
150 kb encoding for at least 80 genes. The genome is divided into long and short unique regions, 
each flanked by characteristic repeated sequences. Genetically altered, conditionally replicating 
HSV has been generated containing a variety of gene deletions and their effectiveness as 
therapeutic agents has been examined in vitro and in vivo in numerous models of metastatic and 
primary tumors. These experiments provide valuable information on the efficacy and safety in the 

UAB Protocol #:  1472   
Version 04.20.2020 
Page 9 
animal models. HSV-1 vectors have the advantage of being neurotropic. Genes essential for HSV-
1 replication in the brain have been identified (12,13). Studies for brain tumor therapy have 
included alterations in one or more of the viral genes thymidine kinase, DNA polymerase, uracil 
DNA glycosylase, ribonucleotide reductase and γ134.5 (14-20). Thymidine kinase, DNA 
polymerase, uracil DNA glycosylase and ribonucleotide reductase are all viral enzymes necessary 
for nucleotide synthesis and replication.  It has been clearly demonstrated experimentally that by 
altering these genes, either by deletion, insertion, or point mutation in the coding region, viruses 
will not be able to replicate in post-mitotic cells such as neurons.  The viruses, however, are able 
to utilize cellular enzymes and factors present in dividing tumor cells to infect and kill them.  
There are two copies of γ134.5 gene; one on each side of the two inverted repeat regions 
of the HSV genome. This gene encodes a critical bifunctional protein that enables the virus to 
replicate in neurons and also blocks a normal host response to infection.  This gene is felt to be 
responsible for the neurovirulence of HSV. In the absence of this protein, the virus fails to induce 
HSV encephalitis even when injected in high amounts into the CNS of susceptible animal models. 
Additionally, a portion of the latency activated transcripts is encoded on the DNA strand opposite 
the γ134.5 genes.  Thus the capacity to express genes necessary for the virus to establish latency is 
lost when the γ134.5 gene is altered. The deletion of the neurovirulence gene produced a greater 
survival of nude mice with human gliomas and retained the tk gene, making it susceptible to 
acyclovir which is considered standard of care treatment for HSV infections (21). Thus, in the 
unlikely event that a mutant virus produces toxicity in normal brain tissue, effective antiviral 
agents are readily available.  
2.3 G207 Development and Preclinical Studies 
G207 is a modified HSV that contains 1) deletions of both copies of γ134.5 and 2) a viral 
ribonucleotide reductase disabled secondary to disruption of the UL39 gene by insertion of the E. 
coli LacZ coding region (16). Both mutations had previously been independently investigated in 
animal models.  The second modification was based on the observation that a virus deficient in 
ribonucleotide reductase (22), a non-essential enzyme for HSV replication in dividing cells, 
showed severe attenuation in non-dividing cells while remaining proficient in killing proliferating 
Vero cells and human tumor cells in culture (21).  These features were incorporated into G207 in 
order to maximally decrease the neurovirulence and yet maintain the ability of the virus to replicate 
in tumor cells.  Other favorable properties of G207 are its easy detection due to the lacZ reporter 
gene, temperature sensitivity, and hypersensitivity to the antiviral drug acyclovir due to the 
retained tk gene, and interruption of the UL39 gene (19). Genetically altered viruses such as G207 
with multiple mutations offer the safest approach for any proposed clinical trial. 
A variety of pediatric tumors, including neural and glial tumors, express the primary HSV 
entry receptor CD111 and are sensitive to engineered HSV both in vitro and in vivo (23-27). When 
comparing the sensitivities of adult and pediatric glioma xenograft lines (xenolines) to G207, 
Friedman et al. demonstrated that the pediatric xenoline was more sensitive than 6 adult xenolines 
tested 
(28). 
Both 
pediatric 
glioma 
cells 
and 
primitive 
neuroectodermal 
tumor 
(PNET)/medulloblastoma cells were sensitive to G207 with a low dose of virus required to kill 
50% of cells in vitro. Furthermore, brain tumor stem cells (also known as brain tumor-initiating 
cells) from pediatric brain tumors were sensitive to γ134.5-deleted HSV suggesting that engineered 
HSV may be able to target this chemotherapy and radiotherapy resistant population (26,27) In 
athymic nude mice bearing intracranial tumors, oHSV prolonged survival significantly with 

UAB Protocol #:  1472   
Version 04.20.2020 
Page 10 
several long-term survivors, including malignant pediatric brain tumors (26,30-31). G207 
significantly prolonged survival of nude mice bearing human tumors either subcutaneously or 
intracranially when injected at titers of 106-107 plaque-forming units (pfu).   
G207 has also been inoculated in young BALB/c mice via four different routes: 
intracerebrally, intracerebroventricularly, intravenously, and intrahepatically with no adverse 
effects or symptoms of disease (32).   In addition, 109 pfu of G207 injected intracerebrally into the 
HSV sensitive owl monkey, Aotus nancymai, did not produce any deleterious side effects, whereas 
103 pfu of HSV-1(F) virus was lethal (33). MRI analysis of G207 treated monkeys showed no CNS 
abnormalities. Neuropathologic evaluation showed local inflammation at the site of injection, but 
no other abnormalities.  HSV DNA was detected throughout the brain by PCR analysis, but the 
unremarkable clinical course of the monkeys has not provided any evidence supporting the clinical 
significance of this finding.  Histopathological evaluation of multiple organs revealed no evidence 
of altered cellular architecture or HSV immunoreactive cells.  
The fundamental difference between G207 and other vector systems is that G207 is a 
conditionally replicating vector capable of replication in tumor cells, but not in the surrounding 
brain tissue. Conditionally replicating HSV is desirable when considering that, following 
resection, more than 109 tumor cells remain in situ. Other methods of treatment, e.g., a retroviral 
vector with the HSV tk, will not likely be able to target this many cells, especially considering the 
ongoing cellular proliferation of the remaining glioma cells. The ability of G207 to selectively 
replicate may allow for the delivery of sufficient vector into the tumor bed to potentially destroy 
most of the cells that remain after conventional therapy. 
As G207 represents an excellent vector for evaluation in clinical studies for the treatment 
of malignant brain tumors, a G207 Master Viral Bank and clinical lot of virus have been produced 
by MediGene, Inc. (Now owned by Treovir, Inc.) in accordance with Good Manufacturing Practice 
(GMP) regulations and tested according to the Points to Consider for the Testing of Cell Lines 
Used in the Manufacture of Biological Products.  
2.4 Genetically-engineered HSV-1 and Radiation 
A number of pre­ clinical studies have combined the selective oncolytic activity of 
genetically modified viruses with radiotherapy. Advani et al. first reported the interaction between 
the modified HSV-1 R3616 (the parent molecule of G207) and radiation (34). In nude mice with 
subcutaneous U87 malignant glioma xenografts implanted in the flank, R3616 injection followed 
by fractionated radiotherapy not only in improved viral replication and distribution, but 
significantly increased tumor regression (observed in 22 of 33 mice receiving combined therapy 
versus 4 of 33 mice receiving R3616 alone). Similarly, a later study used immunohistochemistry 
staining of intracranial glioma xenografts in nude mice to demonstrate a 2- to 5-fold enhancement 
of viral replication when inoculation of R3616 was followed with fractionated radiotherapy (35). 
Longer survival times were observed for the mice in this study receiving the combined therapy, 
and the interaction of radiation and R3616 was significantly shown to be synergistic by statistical 
analysis based on a proportional hazards model.  
Markert et al. observed that although there was not a statistically significant difference in 
the median survival of nude mice with implanted human malignant gliomas that received only 
G207 versus G207 combined with radiation (p=0.09), the latter group was the only group with a 
majority of long­ term survivors (70% in the group receiving combination therapy versus 20-30% 
in the groups receiving either G207 or radiation alone) (20). Of note, this study used two 5 Gy 

UAB Protocol #:  1472   
Version 04.20.2020 
Page 11 
fractionated doses of radiotherapy given at 4 and then 24 hours, doses lower than the prior studies 
and more feasible for delivery in a clinical setting. Further preliminary work has compared the 
survival in mice receiving G207 followed by a single 5 Gy dose of irradiation given at varying 
time intervals (4 hours, 24 hours, and 120 hours). The group receiving radiation at 24 hours has 
demonstrated markedly improved survival over the groups receiving radiation at 4 or 120 hours 
(60% versus 30-40% at 91 days) (G.Y. Gillespie, personal communication). 
Importantly, none of the pre-clinical in vivo studies observed any mortality that could be 
attributed to a potential adverse synergism of these two modalities. 
Several mechanisms have been proposed to explain the observed in vivo synergism of G207 
and radiation. Because viruses with varying mutations have shown enhancement in response to 
radiation (Advani et al. observed a similar response in a second HSV-1 mutant), it appears unlikely 
that the irradiated cells are simply increasing production of a single protein which substitutes for 
a missing viral gene function, although Stanziale, et al, showed that radiation potentiated the 
antitumor efficacy of G207 by upregulating ribonucleotide reductase (34, 36). Since the HSV 
mutants replicate more efficiently in dividing tumor cells, it has been hypothesized that the 
enhanced viral replication may be accountable to a higher proportion of tumor cells in S phase 
after radiation. Other theories suggest that tumor cells may modify cytokine expression in response 
to radiation, or that the local inflammatory response to radiation may somehow facilitate increased 
viral replication within the tumor cells (20).  Although the mechanisms underlying this synergy 
have not been fully elucidated, the results of the pre-clinical trials nonetheless provide strong 
rationale to begin investigating the safety of these combined modalities in humans. 
2.5 Previous Clinical Experience 
A Phase I clinical trial in adults was completed in March 2000 under BB-IND-7393 with 
HSV G207 (1).  The genetically altered virus was supplied as clinical grade virus by the study 
sponsor, MediGene, Inc.  Twenty-one adult patients with recurrent malignant glioma (GBM or 
anaplastic astrocytoma) were treated in seven cohorts of three each by stereotactic intratumoral 
injection of HSV G207 in a standard dose escalation fashion.  Doses ranged from 1 x106 pfu as a 
single injection in 100 to 300 µl up to 3 x 109 pfu given at 200 µl each in five sites. While some 
patients developed complications frequently seen in patients with high-grade gliomas, no toxicity 
or serious adverse events could unequivocally be ascribed to G207.  In fact, a toxic dose level was 
not reached during this trial because available viral production techniques limited the total dose 
that could be administered. There was also radiographic and neuropathologic evidence suggestive 
of anti-tumor activity and long-term presence of viral DNA in some cases. In a phase Ib study, 6 
patients with recurrent GBM received two doses (one administered pre-tumor resection and one 
post resection in the resection cavity) of G207 totaling 1.15 x 109 pfu (2).  Viral replication was 
demonstrated and radiographic and neuropathologic evidence suggestive of antitumor response 
was reported. No patient developed HSV encephalitis or required treatment with acyclovir.  
A third Phase I study examined the safety of stereotactic intratumoral administration of 
G207 followed within 24 hours with a single 5 Gy radiation dose in patients with recurrent 
malignant gliomas. Treatment was well tolerated and no dose limiting toxicities were experienced. 
Importantly, 6 of 9 patients had a stable or partial response for at least one time point. The safety 
established in these three studies forms the basis to extend HSV G207 to the pediatric population. 
Pediatric patients may respond differently than adults to G207. They are more likely to be 
seronegative for HSV at the time of injection, and therefore will require close monitoring for 
seroconversion and/or any evidence of HSV related sequelae, especially encephalitis.   

UAB Protocol #:  1472   
Version 04.20.2020 
Page 12 
2.6 Safety Information 
The safety of G207 has been addressed both by the deliberate molecular engineering of the 
virus (as discussed in Section 2.3), as well as by extensive in vitro and in vivo testing of precursors 
to the clinical material, as well as on the clinical material.  In vitro testing has included the 
following: 
 
SUMMARY OF G207 TESTING 
G207 Master Virus Bank (MVB) 
Test 
Result 
Bulk Cell Harvest 
 
Sterility 
Pass 
Mycoplasma 
Negative 
Final Filled Vials 
 
Sterility (21 CFR 610.12) 
Pass 
 
 Lot Release (7/3/97) 
Test 
Result 
Bulk Cell Harvest 
 
Sterility 
Pass 
Mycoplasma 
Negative 
Final Filled Vials: Sublot A 
 
Sterility (21 CFR 610.12) 
Pass 
General Safety (21 CFR 610.11) 
Pass 
LAL 
9.8 EU/mL 
Final Filled Vials: Sublot B 
 
Sterility (21 CFR 610.12) 
Pass 
General Safety (21 CFR 610.11) 
Pass 
LAL 
< 1.0 EU/mL 
Bacteria/Fungistasis USP XXII 
Pass 
 
HSV infection is widespread among healthy adults and children alike.  Influenced by 
socioeconomic and geographic factors, HSV seropositivity in children five years of age is 20-30%; 
this increases to 40-80% by the second decade of life (37).  In the Phase I study with G207 in 
adults, only 1 of 5 seronegative patients demonstrated seroconversion after G207 administration. 
Importantly, no specific clinical decline seemed to be attributable to this seroconversion, therefore 
suggesting that children may not be at an increased risk secondary to their lower incidence of 
seropositivity. Although neonates are more susceptible to the development of HSV encephalitis 
(HSE) than adults (the sensitivity of a human neonate is generally equivalent to the sensitivity of 
Aotus nancymai), other pediatric patients beyond the neonatal period develop HSE at an incidence 
similar to that in adults (one in 200,000 individuals).   
Although HSE most often presents in neonates with generalized symptoms, HSE in adults 
and older children typically produces specific disturbances of the normal functions of the involved 
brain.  It is unknown, however, if pediatrics patients will be more susceptible than adults to 
developing HSE or other herpes related infection after treatment with G207.  Patients will be 

UAB Protocol #:  1472   
Version 04.20.2020 
Page 13 
closely monitored during the clinical studies for indications of HSE (see Section 7.4) as well as 
other possible side effects with the administration of G207. In the event of the development of 
HSE, the tk gene, which confers sensitivity to gancyclovir and acyclovir, remains intact, allowing 
for medical management with high-dose acyclovir according to established methods (14).  In 
general, children tend to have more complete recovery from HSE than adults who are >30 years 
of age (38). 
Unlike whole brain radiotherapy, inoculation of G207 is a focal intervention, and as such 
is not expected to produce any neurodevelopmental insult in the pediatric patient greater than that 
which would be expected for other standard focal interventions in patients with this disease 
(surgery or focal radiation).  The single 5 Gy dose of radiation proposed is to enhance virus 
replication and cancer cell killing (see Section 2.3.2) and was well tolerated in the adult Phase I 
study when combined with G207 (3). Palliative fractionated reirradiation at total doses up to 18 to 
35 Gy has been safely used in children and adults with a variety of recurrent brain tumors (39-41). 
The patient population to be studied will have been heavily pretreated most likely with radiation 
and chemotherapy.  They are therefore likely to have neurocognitive deficits upon entry into this 
study. 
3.0 Study Objectives: 
3.1 Primary Objective:   
To assess the safety and tolerability of G207 administered intratumorally via controlled 
rate infusion alone or followed by a single dose of radiation within 24 hours of G207 administration 
in children with recurrent or progressive malignant supratentorial brain tumors. Safety/tolerability 
will be assessed by adverse events and laboratory tests. The dose escalation scheme for this study 
was based on the adult phase I study in which the maximum planned dose of 3 x109 was 
administered without significant adverse effects. The MTD or maximal planned dose, if no dose-
limiting toxicity is observed, will be determined. 
3.2 Secondary objective:  
To obtain preliminary information concerning the potential efficacy of and biological 
response to G207 alone or combined with a single dose of radiation in pediatric patients with 
recurrent or progressive malignant brain tumors. This will be assessed by measuring radiographic 
response, determining patient performance scale, progression-free and overall survival, measuring 
antiviral immune response and presence of G207 in blood, saliva, and conjunctiva. The impact of 
this new therapy on patients' quality of life will also be assessed (optional consent).  
4.0 Study Design: 
4.1 Overview 
Pediatric patients with recurrent or progressive supratentorial malignant brain tumors who 
have failed surgery, radiotherapy and who may or may not have had chemotherapy or other form 
of treatment will be eligible for the study. An MRI must demonstrate progression of residual tumor 
at least eight weeks after radiation treatment. Last chemotherapy must be 3 or more weeks from 
entry and patients must have normal hematologic function.  Patients must be on a stable dose of 
steroids for at least one week prior to injection. HSV immune status will be determined both pre- 
and post-treatment. 
The general principles underlying the therapeutic strategy of this trial will be explained in 

UAB Protocol #:  1472   
Version 04.20.2020 
Page 14 
non-medical, lay language to the patient and/or the patient's caretakers.  Potential risks and benefits 
will be discussed, as well as the time involvement necessary for appropriate follow-up care. 
Alternative therapies for pediatric patients with recurrent/progressive malignant brain tumors will 
be discussed, including standard (re-resection, repeat fractionated radiotherapy, and/or 
chemotherapy) and experimental (biological agents, gene therapy, and novel combinations and 
administration routes of existing agents) interventions. The patient's caretaker(s) will be provided 
with a summary of this information as contained in the informed consent form, and will be given 
as much time as needed to make a deliberate decision concerning the involvement of their child in 
this trial.  While those who do not decide to enroll in this trial will be provided with the best 
standard of care available, those consenting to enrollment will undergo the following procedures. 
Under general anesthesia, patients will undergo stereotactic image-guided craniotomy, 
stereotactic biopsy and intraoperative histopathological analysis to document tumor cells, followed 
by placement of 1-4 catheters for G207 inoculation. Treatment with G207 will only proceed if 
viable, recurrent tumor is present on the frozen section. Three patients will be entered at each dose.  
The initial dose will be 1 x 107 pfu of G207 in a volume of 2.4 ml for the first three patients.  If no 
significant (Grade 3 or 4) toxicities are encountered within 28 days of completing this treatment 
cohort, a subsequent dose level of 1 x 108 will be used. If no dose limiting toxicities are seen at 
either dose level, the initial dose level (1 x 107) will be repeated followed by a single 5 Gy fraction 
of radiation directed to the tumor within 24 hours of G207 inoculation. If deemed safe, a final dose 
level of 1 x 108 combined with a single dose of 5 Gy of radiation will be used. If two or more 
patients have toxicity at the starting dose, a cohort will be added at 1 x 106.  If two or more patients 
have toxicity at this lower dose, the study will be terminated.  The maximally tolerated dose (MTD) 
will be defined as the dose immediately below any dose that causes Grade 3/4 toxicities in 2 
patients.  There will be a minimum 28 day observation period between the first and second patient 
of each cohort, a seven-day observation period between patient two and three enrolled in a cohort, 
and a 28 day observation period from one cohort to the next to allow for evaluation of potential 
toxicity.  Patients will be followed closely with potential effects of HSV being monitored closely. 
Medical monitors with expertise in diagnosis and treatment of herpes encephalitis will review all 
patient data and will be available for immediate consultation should any suspicion or concerns for 
infection arise. HSV antibody titers will be measured pre-operatively, and at 1, 3, 5, 7, 9 and 12 
months.  PCR and cultures will also be performed at the same time points to check for HSV in 
saliva and conjunctival secretions and PCR for HSV in blood. MRI will be done on day 3 or 4 after 
treatment and at months 1, 3, 5, 7, 9 and 12.  Patients whose tumor shows radiographic and clinical 
evidence of progression will be declared a treatment failure and may be considered as candidates 
for any other available therapy (as described above).  Nonetheless, patients who have received 
G207 will continue long-term follow-up even after receiving other cancer therapies. 
4.2 Sample Size Considerations 
This Phase I study is conducted using a traditional (3+3) dose escalation design with four 
dosing cohorts. Thus the sample size for this study is up to 24 patients. In each cohort, 3 patients 
will be initially enrolled. Once the cohort of three patients has completed the toxicity and safety 
evaluation, additional patients will be enrolled into the next cohort or current cohort expanded 
following the dose escalation rules. Sample size has been determined based on practical 
consideration of the traditional 3+3 Dose Escalation design. Although accrual is expected to take 
24-30 months for 12 patients, the actual time necessary for accrual is difficult to estimate due to 
an inability to predict the degree of toxicity that will be observed. 

UAB Protocol #:  1472   
Version 04.20.2020 
Page 15 
4.3 Statistical Considerations  
This study is a Phase I clinical trial, standard dose-escalation study of safety and toxicity. 
A standard 3 + 3 design will be used. It is anticipated that patients with several different 
histologic tumor types will be enrolled in this study, since the primary endpoint is safety and not 
efficacy. Data from the study will be presented in a descriptive manner with careful analysis of 
any effects that G207 may have on survival, cognitive function, or development of herpes 
infection. In general, descriptive statistics will be used to summarize the safety and efficacy 
variables collected and the baseline demographic data. Continuous variables will be summarized 
using mean, standard deviation, minimum, median, and maximum. Categorical variables will be 
summarized using frequency counts and percentages. Additional exploratory analyses of the data 
on some of the secondary endpoints will be conducted as deemed appropriate. 
4.4 Treatment Summary  
Dosing will start at an initial dose level of 1 x 107 pfu of G207, and will then escalate by 
one log increment to a dose of 1 x 108 pfu. If there are no unacceptable dose-limiting toxicities, 
the dose levels will be repeated in combination with a single 5 Gy dose of radiation. Subjects will 
be enrolled sequentially. Treatment will be escalated as follows:  
 
Dose Level 
Patients 
Dose (pfu) 
Volume 
# Loci 
-1 
3 
1x106 
2.4 ml 
1-4 
1 
3 (+3) 
1x107 
2.4 ml 
1-4 
2 
3 (+3) 
1x108 
2.4 ml 
1-4 
3 
3 (+3) 
1x107 + 5 Gy radiation 
2.4 ml 
1-4 
4 
3 (+3) 
1x108 + 5 Gy radiation 
2.4 ml 
1-4 
 
There will be a minimum 28 day observation period between the first and second patient of each 
cohort, a seven-day observation period between patient two and three enrolled in a cohort, and a 
28 day observation period from one cohort to the next to allow for evaluation of potential toxicity. 
A dose limiting toxicity (DLT) is defined as any Grade 3 or 4 toxicity (NCI CTCAE v.5.0) that is 
considered as being possibly, probably or likely related to G207 within 30 days of G207 
inoculation with the following exceptions: 
 
1) Neurologic deterioration will not be considered dose-limiting if it resolves back to the 
patient’s baseline within two weeks of receiving G207. For example, increased weakness 
or aphasia that occurs during the infusion will be treated with increasing steroid doses 
and/or slowing of infusion rates, but not treated as a DLT 
2) Any Grade 3 or 4 neurological toxicity that improves with supportive care agents 
(bevacizumab and/or steroids) or that is determined to be tumor progression by the 
treating physician.  
3) Any Grade 4 seizure that improves within 48 hours of initiation of supportive care 
measures.   
Due to the possibility of pseudoprogression, a well-known entity seen in oncolytic viral therapy, 
as outlined in section 6.4.7., neurological changes may be treated with supportive care agents, 
bevacizumab and/or steroids. Improvement of symptoms with supportive care agents will not be 
considered a dose limiting toxicity (DLT). For example, increased weakness or aphasia that occurs 
during the infusion will be treated with increasing steroid doses and/or slowing of infusion rates, 

UAB Protocol #:  1472   
Version 04.20.2020 
Page 16 
but not treated as a DLT if symptoms improve to baseline within seven days of completing 
treatment. If one patient has a DLT at the starting dose, up to 3 additional patients will be treated 
at that dose.  If two or more patients have toxicity at the starting dose, a cohort will be added at 1 
x 106.  If two or more patients have toxicity at this lower dose, the study will be terminated. If 
significant toxicity is encountered in one patient at subsequent dose levels, patient numbers will 
be increased to six for that dose level. If no further toxicity is observed, the dose escalation will 
continue. If 2 patients in a cohort have any Grade 3 or 4 non-hematologic toxicity, as defined by 
NCI CTCAE v.5, that is considered as being possibly, probably or likely related to G207, the dose 
level immediately below will be defined as the MTD.  If only 3 patients had previously received 
the newly determined MTD (because no Grade 3/4 toxicity was observed), a second cohort of 3 
patients will receive that dose to ensure that it is indeed safe. If there are no DLTs in the highest 
cohort, 3 additional patients will be added to ensure safety at that dose. 
4.5 Stopping Rules 
The study will be stopped if the MTD is established or if the lowest proposed dose causes 
unacceptable toxicity. The medical monitors and/or principal investigator will apply the stopping 
rules. The study will be paused for the following events: death (except due to motor vehicle 
accident or clear progressive disease), two instances of Grade 4 toxicity, disseminated HSV 
infection, or any severe, life-threatening neurologic complications including uncontrolled seizures 
of 48 hours, HSV encephalitis, or mental status changes requiring intubation. The pause will be in 
effect to allow assessment by the medical monitors, principal investigator, UAB Comprehensive 
Cancer Center Clinical Trials Monitoring Committee (CTMC), and the FDA to review the events 
to decide if the study should be terminated or can be resumed.   
4.6 Data and Safety Monitoring 
All patient data will be maintained on UAB computers with appropriate password 
protection. A nurse clinician with expertise in clinical trials and the principal investigator will be 
responsible for all data collection and maintenance.  This project will be conducted under the 
oversight of the UAB Comprehensive Cancer Center for which a Data and Safety Monitoring Plan 
has been established.  This study will be under the supervision of the UAB CTMC which acts as 
a Data Safety and Monitoring Committee for patients with brain tumors who are enrolled in clinical 
trials at UAB. There is no Data and Safety Monitoring Board for this Phase I study.   
5.0 Study Population: 
5.1 Inclusion Criteria 
Patients meeting the following inclusion criteria will be eligible for the study: 
5.1.1 Age ≥ 36 months and < 19 years    
5.1.2 Pathologically proven malignant supratentorial brain tumor (including 
glioblastoma multiforme, giant cell glioblastoma, anaplastic astrocytoma, 
primitive neuroectodermal tumor, ependymoma, atypical teratoid/rhabdoid tumor, 
germ cell tumor, or other high-grade malignant tumor) which is progressive or 
recurrent despite standard care including surgery, radiotherapy, and/or 
chemotherapy. A pathologically proven secondary malignant tumor without 
curative treatment options is eligible. 
5.1.3 Lesion must be ≥ 1.0 cm in diameter and surgically accessible as determined by 

UAB Protocol #:  1472   
Version 04.20.2020 
Page 17 
MRI 
5.1.4 Patients must have fully recovered from acute treatment related toxicities of all 
prior chemotherapy, immunotherapy or radiotherapy prior to entering this study.  
5.1.5 Myelosuppressive chemotherapy: patients must have received their last dose at 
least 3 weeks prior (or at least 6 weeks if nitrosurea) 
5.1.6 Investigational/Biologic agents: patients must have recovered from any acute 
toxicities potentially related to the agent and received last dose ≥ 7 days prior to 
entering this study (this period must be extended beyond the time during which 
adverse events are known to occur for agents with known adverse events ≥ 7 
days). For viral therapy, patients must have received viral therapy ≥ 3 months 
prior to study entry and have recovered from all acute toxicities potentially related 
to the agent 
5.1.7 Monoclonal antibodies: patient must have received last dose ≥ 21 days prior.  
5.1.8 Radiation: Patients must have received their last fraction of craniospinal radiation 
(>24 Gy) or total body irradiation ≥ 3 months prior to study entry. Patients must 
have received focal radiation to symptomatic metastatic sites or local palliative 
radiation  ≥ 28 days  prior to study entry. 
5.1.9 Autologous bone marrow transplant: Patients must be ≥ 3 months since transplant 
prior to study entry. 
5.1.10 Normal hematological, renal and liver function (Absolute neutrophil count > 
1000/mm3, Platelets > 100,000/mm3, PT or PTT < 1.3 x control, Creatinine 
within normal institutional limits OR creatinine clearance >60 mL/min/1.73 m2 
for patients with creatinine levels above institutional normal, Total Bilirubin < 1.5 
mg/dl, Transaminases < 3 times above the upper limits of the institutional norm) 
5.1.11 Patients < 10 years, Modified Lansky score ≥ 60; patients ≥ 10 years, Karnofsky 
score ≥ 60 
5.1.12 Patient life expectancy must be at least 8 weeks 
5.1.13 Written informed consent in accordance with institutional and FDA guidelines 
must be obtained from patient or legal guardian 
5.2 Exclusion Criteria 
Patients with the following conditions will be excluded from participation in the study: 
5.2.1 Any treatment outside the allowable guidelines outlined in section 5.1. 
5.2.2 Acute infection, granulocytopenia or medical condition precluding surgery 
5.2.3 Pregnant or lactating females 
5.2.4 Prior history of encephalitis, multiple sclerosis, or other CNS infection 
5.2.5 Tumor involvement which would require ventricular, cerebellar or brainstem 
inoculation or would require access through a ventricle in order to deliver 
treatment     
5.2.6 Required steroid increase within 1 week prior to injection 

UAB Protocol #:  1472   
Version 04.20.2020 
Page 18 
5.2.7 Known HIV seropositivity 
5.2.8 Concurrent therapy with any drug active against HSV (acyclovir, valacyclovir, 
penciclovir, famciclovir, gancyclovir, foscarnet, cidofovir) or any 
immunosuppressive drug therapy (except dexamethasone or prednisone). 
6.0 Study Methods and Procedures: 
6.1 Designated Laboratories/Central MRI Review 
6.1.1 Routine chemistry and hematology will be performed by a CLIA certified 
laboratory.  
6.1.2 All viral culture and viral serology will be performed by a Diagnostic Virology 
laboratory. 
6.1.3 MRI/CT will be reviewed by a designated pediatric neuroradiologist. 
6.1.4 All pathology will be reviewed by a pediatric neuropathologist. 
6.2 Screening Evaluations 
Prior to treatment, patients will undergo physical examination, neurologic evaluation and 
routine preoperative clinical laboratory testing as well as collection of saliva and conjunctival 
secretions for HSV culture and PCR and blood for HSV PCR. After having undergone a 
preoperative evaluation consistent with inclusion in the study, the study participant will undergo a 
contrast-enhanced MRI scan. Sedation will be used during the MRIs as necessary for the patient's 
comfort. Review of these MRI scans will be necessary to determine if the tumor location and size 
is such that the patient may be included in the study. Tumor size will be determined using the 
maximal 2-dimensional cross-sectional tumor measurements, transverse x width, using either T1 
or T2 weighted images. This imaging study will be obtained a maximum of 14 days prior to the 
patient’s stereotactic inoculation.  Also obtained within this timeframe will be assessment of 
quality of life by a neuropsychologist. 
6.3 Intratumoral Inoculation with G207 
After informed consent has been obtained and all screening procedures completed 
according to the protocol, craniotomy and biopsy may commence. The patient will undergo a 
contrast enhanced MRI study using a frameless stereotactic system protocol. Utilizing the 
frameless stereotactic system, children under general anesthesia will undergo a stereotactic 
guided craniotomy. First, a frozen section biopsy for histopathological confirmation of 
neoplastic cells will be taken.  If tumor is not present on frozen section, patients will not 
undergo G207 inoculation. Following frozen section demonstration of recurrent tumor, up to 
4 silastic catheters (PIC-030 or equivalent: (30cm x 2.0mm outer diameter, 1.00mm inner 
diameter) Neuro-Infusion Catheter, equipped with a stainless steel stylet and a 6 French 
compression hub) will be passed to stereotactically predefined coordinates of enhancing tumor, 
if present. Catheters may be placed in non-enhancing regions if residual tumor is confirmed in 
those locations. The catheters will be exteriorized, primed with sterile vehicle (Dulbecco's 
Phosphate-buffered saline + 10% glycerol; Alanza, Inc.) for injection, the scalp wound(s) 
closed and the patient allowed to recover in the Pediatric Intensive Care Unit (PICU). While 
in the PICU, vital signs (temperature, blood pressure, pulse, respiratory rate) and neurologic 
function (Glasgow Coma Scale and limited neurological exam) will be monitored every hour 
overnight according to the PICU standard for intensive monitoring. The following day, a 

UAB Protocol #:  1472   
Version 04.20.2020 
Page 19 
postoperative CT scan will be obtained to confirm the location of each catheter within the 
tumor. If needed, and it is possible to do so at the bedside, the surgeon will adjust the position 
of the catheter tip by slightly withdrawing it to a more desirable location. Otherwise, mal-
placed catheters will not be utilized for the infusion of virus.  
The total amount of G207, as defined by each patient’s dose level, will be delivered in a 
total volume of 2.4 ml administered in up to four catheters, each attached to a separate syringe 
mounted in a microprocessor-controlled infusion pump for a total infusion rate of 400 
microliters (0.4 ml) per hour for 6 hours. However, the infusion will actually last 6 hours and 
36 minutes to allow flushing of the saline solution from the catheter(s).  The infusion rate for 
the flush will be 400 microliters (0.4 ml) per hour for 36 minutes per catheter. After the 36 
minute flush, the infusion rate will be changed to the appropriate rate for the G207 infusion. 
Following the flush, the rate of administration through each individual catheter shall be 
determined by the equation: 
400 microliters (0.4 ml) per hour/number of active catheters. 
The total volume administered from each syringe will be determined by the number of 
catheters actively infusing, using a volume of 400 microliters (0.4 ml) per hour as a guide.  
Refer to table below. 
 
 
 
For the study drug infusion, the study drug syringe will be connected to the infusion tubing, 
that has been flushed with sterile PBS + 10% glycerol (Alanza). The infusion tubing (PIT-400, 
Sophysa) will then be primed with 4 ml of the diluted G207 virus preparation in the syringe 
and connected to the catheter. The infusion period will begin with the 36 minute flush of the 
saline solution from the catheter. After completion of the flush the pump will be reprogramed 
to the appropriate rate for the study drug infusion and the infusion initiated for 6 hours.  This 
interval was chosen based on previous stability testing to ensure no detectable loss of virus 
activity.  
If delivery at the desired rate is not possible through an individual catheter, the rate of 
delivery through that catheter may be slowed and the rate of delivery through the remaining 
catheters increased as possible to attempt to maintain total delivery rate at 400 microliters (0.4 
ml) per hour. Infusion may extend up to 8 hours, if needed due to catheter malfunction.   
6.4 Patient Management Following Virus Infusion 
At the start of the virus infusion, vital signs and neurologic function will be monitored 
every hour x 6, then every two hours overnight for the first 24 hours. At least one hour after 
Table :  Plan for Loading rate and Infusion Rate for G207 HSV 
Number of 
Catheters 
Initial Loading Rate for  
First 36 mins per catheter 
Final Infusion Rate per 
catheter 
1 
0.4 cc/hour 
0.4cc/hour 
2 
0.4 cc/hour 
0.2cc/hour 
3 
0.4 cc/hour 
0.13cc/hour (for 2 catheters); 
0.14cc/hr (for 1 catheter) 
4 
0.4 cc/hour 
0.1cc/hour 

UAB Protocol #:  1472   
Version 04.20.2020 
Page 20 
completion of the virus infusion, the catheter(s) may be removed at the bedside by the 
neurosurgeon team. Patients that appear stable after removal of the catheter(s) may be moved to a 
general inpatient room, and the frequency of monitoring will be determined by the attending 
physician(s) based on the medical condition of the patient.  
6.4.1 FOCAL NEUROLOGICAL DEFICITS: General neurologic worsening (decreased 
state of consciousness) including focal neurological deficits or specific 
neurological worsening (paresis, dysphasia, etc., depending upon location of 
tumor), could be due to edema, hematoma, hydrocephalus, or encephalitis. An MRI 
or CT will be done to help determine the cause. 
6.4.2 CEREBRAL EDEMA: This is common in tumor patients and occurs post-
operatively and usually responds to standard measures for the treatment of 
increased intracranial pressure.  Although medical management with systemic 
steroids is often very effective, patients occasionally require a ventriculostomy or 
surgical shunting procedure. 
6.4.3 HEMATOMA: PT, PTT, and platelet count will be obtained. A small hematoma 
noted on a scheduled MRI may simply be watched and the patient treated as above 
for edema and then rescanned to exclude an enlarging lesion. A large hematoma or 
one associated with progressive neurologic deterioration may require operative 
evacuation. 
6.4.4 ENCEPHALITIS: Patients who develop fever >101.5F and/or alterations in mental 
status/waning Glasgow Coma Scale, or seizures will immediately undergo general 
physical and neurologic examination. If the patient has fever without any 
neurologic signs/symptoms, source for systemic infection will be investigated. If 
no source for fever can be found and fever persists for greater than 12 hours, 
evaluation for encephalitis will take place. Patients who have neurologic changes 
as above will also undergo immediate evaluation for encephalitis. CT or MRI will 
be performed.  If this study demonstrates an increase in the area of hemorrhagic 
necrosis extending beyond the borders of the tumor Post-operative bed, a 
stereotactic biopsy will be taken to assess for presence of G207 or HSV-1(F) virus. 
This will consist of a minimum of 2-3 needle core biopsies which will undergo 
standard hematoxylin and eosin (H&E) staining, as well as immunostaining for 
HSV-1, PCR and culture, CD68, leukocyte common antigen, glial fibrillary acidic 
protein (GFAP), and X-gal staining for the beta-gal product. This will be reviewed 
by a Pediatric Neuropathologist. While waiting for biopsy results, the patient will 
be empirically started on intravenous acyclovir at a dose of 30 mg/kg divided every 
8 hours. At the time of biopsy, a sample of CSF will be obtained if safe and checked 
for HSV by PCR to rule out HSV meningitis. Patients whose clinical course is 
suggestive of HSV encephalitis but imaging studies do not show a change from 
baseline, will undergo lumbar puncture for CSF examination as well.  Those 
patients will be treated with empiric acyclovir as well.  Patients who have tissue, 
CSF, or strong clinical evidence for HSV encephalitis will be treated for a 14-day 
course of acyclovir therapy. The medical monitor will be consulted immediately 
for any suspected cases of encephalitis and be integrally involved in evaluation and 
treatment decisions.         

UAB Protocol #:  1472   
Version 04.20.2020 
Page 21 
6.4.5 DISSEMINATED HSV: Disseminated multi-organ disease attributed to HSV is 
exceedingly uncommon, even in the immunocompromised host.  Such disease has 
been encountered in newborns with disease identified as ‘disseminated multi-organ 
involvement’ and occurs in about 25% of newborns with this disease (incidence 
1:10,000 deliveries) (42).  In all circumstances, disseminated disease is associated 
with a systemic host response of fever, and findings compatible with sepsis, 
including hepatic dysfunction. To monitor for these rare events, most importantly, 
serial physical examinations will be performed to assess for fever and symptoms of 
sepsis or hepatic dysfunction. In addition, serial blood specimens will be obtained 
and cultured for infectious HSV at days 1, 3 or 4, 7, 14, 28; months 3, 5, 7, 9, 12, 
18, 24; and yearly thereafter. Any positive cultures will be analyzed by PCR to 
discriminate between wild type HSV-1 and mutant G207 HSV.  Should a patient 
develop fever, rash, or unexplained elevations in liver function tests in conjunction 
with a concomitant increase of infectious HSV by plaque assay in blood specimens 
(exceeding prior values by 2 logs), patients will undergo a 21 day course of 
treatment with acyclovir at a dose of 30mg/kg divided every 8 hours for presumed 
disseminated HSV infection. The medical monitor will be consulted immediately 
for any suspected cases of disseminated HSV and be integrally involved in 
evaluation and treatment decisions. Parenthetically, it should be noted that 
oncolytic HSV therapy for metastatic colon carcinoma involving the liver led to 
detectable HSV DNA in the blood but in the ABSENCE of clinical 
symptomatology (43); thus, increasing levels as well as fever will both be required 
to therapeutically intervene. Should two Grade 3 or 4 toxicities attributable to 
disseminated HSV infection occur in the same dose level, the prior dose level shall 
be declared the MTD and enrollment will be halted.  
6.4.6 VIRAL SHEDDING DUE TO CSF LEAK OR BODY FLUID VIRAL 
CONTAMINATION: Patients with CSF leak will receive the standard of care by 
neurosurgery to close the leak. HSV PCR of the CSF will be performed prior to 
closure. Any abnormal fluid collection at the surgical site will be assessed by 
neurosurgery and HSV culture and PCR of the fluid will be performed. Any signs 
of encephalitis or HSV dissemination will be managed as outlined above.  Patients 
will be assessed for HSV shedding from body fluids (saliva, conjunctival 
secretions, and blood) routinely throughout the study (see Appendix A). Any 
patients with body fluid viral contamination will be placed on contact precautions 
until there are two negative follow-up samples.  
6.4.7 PSEUDOPROGRESSION:  Pseudoprogression is a well-known entity in oncolytic 
viral therapy, immunotherapies, and the treatment of malignant brain tumors (44, 
45). Patients with possible pseudoprogression may be watched or treated with 
bevacizumab, which has been shown to ameliorate symptoms of pseudoprogression 
or radiation necrosis, and/or dexamethasone at the discretion of the investigators 
(46-49). If the patient improves with bevacizumab and/or additional steroid 
administration (to be used if bevacizumab is contraindicated or insufficient) and the 
MRI changes in lesion size/and or enhancement also improves, the patient will be 
determined to have not progressed but to have had pseudoprogression, and will 
continue follow-up within the trial under the previously defined schedule. Should 
neurologic symptoms and/or imaging changes progress despite steroid 

UAB Protocol #:  1472   
Version 04.20.2020 
Page 22 
administration on follow-up imaging, the patient will be determined to have 
progressed and the date of progression shall be assigned to the date of the initial 
scan that demonstrated findings consistent with progressive disease as defined in 
section 9.2.1. For patients that are symptomatic despite bevacizumab and/or 
steroids, surgical resection of the lesion may be recommended to remove necrotic 
tissue and any residual tumor.   
6.5 Radiation Planning and Treatment 
For patients receiving radiation, a 100 SAD linear accelerator with at least 6 MV beam 
energy will be utilized for radiation treatment. 
6.5.1 Simulation and Immobilization 
All patients will undergo simulation and radiation treatment. Simulation may occur at 
the screening visit or on postoperative day 1. The patient will generally be placed in 
the supine position, but prone positioning is allowed. A custom aquaplast 
immobilization device will be fabricated and axial CT images will be collected at a 
slice thickness less than 3 mm. 
6.5.2 Target Volumes and Treatment Planning 
The postoperative MRI will be utilized for treatment planning. This study will be 
registered/fused to the simulation CT scan. The target volumes and prescription 
doses for RT planning are shown in the table below and follow ICRU-62 
conventions. The goal of treatment planning is coverage of the PTV1 and PTV2 by 
the prescription 100% isodose line with none of the PTV1 to receive greater than 120% 
(6 Gy). The dose to brainstem and optic apparatus (nerves and chiasms) should be 
limited to 3 Gy or less unless coverage of the GTV would be compromised. The 2 mm 
margin for setup and registration error may be dosimetrically compromised in cases 
which gross tumor is very close to critical structures such as the brainstem or optic 
apparatus. In no case should gross disease receive less than the prescription dose. For 
tumors that do not have T1 abnormality, high risk portions of the T2 or FLAIR 
abnormality should serve as the GTV. 
 
Volume 
Abbreviation 
Definition 
Dose 
Gross Tumor Volume 
GTV 
T1 gross residual disease 
- 
Clinical Target Volume 
CTV 
T2 or FLAIR abnormality 
- 
Planning Target Volume 1 PTV1 
GTV plus 2 mm 
5 Gy 
Planning Target Volume 2 PTV2 
CTV plus 2 mm 
3 Gy 
 
Generally, it is expected that multiple axial or non-axial beams (5-9) will be 
required to generate an acceptable plan. Field segmentation will often allow 
differential dosing to the PTV1 and PTV2 without computer optimization. 
Computer optimization and intensity modulated radiation therapy are allowed 
but not required. Plans utilizing computer optimization will need ion chamber 
measurement before delivery. 
The 
treating 
radiation 
oncologist 
must 
review 
all treatment 
and 
setup/localization films before treatment. 

UAB Protocol #:  1472   
Version 04.20.2020 
Page 23 
6.6 Supportive Care Guidelines 
Appropriate supportive care during the duration of the study includes the following: 
6.6.1 Bevacizumab or steroid administration for neurologic symptoms arising from 
increased edema or intracranial pressure if deemed appropriate and safe in the 
determination of the investigator. Bevacizumab may be given at least 14 days after 
initial surgery for biopsy and catheter placement to allow adequate time healing of 
the surgical incision. Bevacizumab will be given every two weeks at a dose of 5-
10 mg/kg IV. Dosage adjustments or cessation of drug may be made should adverse 
events related to bevacizumab occur (e.g. uncontrolled hypertension, proteinuria, 
bleeding, thrombosis, etc.) and are made on a case-by-case basis by the prescribing 
neuro-oncologist. Previous tumor progression on bevacizumab does not preclude 
its use herein. An increase in steroid dose will be kept to a minimum as patient 
neurologic condition permits. 
6.6.2 Proton pump inhibitors or H2 antagonists for control of steroid-induced gastric 
irritation 
6.6.3 Anti-epileptic medicines for control of partial or generalized seizures 
6.6.4 Post-operative neurological intensive care that is routine for the neurosurgical 
interventions involved in the administration of G207 
6.6.5 Other than a restriction on medications with anti-HSV activity (to be given only for 
the management of an adverse event), there are not any limitations on concomitant 
medications that patients may receive for other co-morbidities. 
6.7 Study Evaluations by Time Point (Appendix A) 
6.7.1 Prescreening/Screening 
 
Vital signs (temperature, blood pressure, pulse, respiratory rate) 
History and Physical including complete neurological status on exam 
 
Modified Lansky or Karnofsky status determination (Appendix B) 
 
Complete metabolic panel (CMP), magnesium, phosphorous, Complete blood 
count with differential and platelets (CBC) including lymphocyte markers 
 
Cystatin C (if creatinine is elevated from institutional normal value) 
 
HIV serology 
 
HSV antibody titer 
 
HSV detection (HSV culture saliva, conjunctival secretions; HSV PCR saliva, 
conjunctival secretions, blood) to rule out viral shedding and/or viremia 
 
Serum pregnancy (adolescent females) and urinalysis 
 
PT/PTT 
 
MRI with and without contrast of brain to evaluate tumor and assess for placement 
of catheter(s) 
 
6.7.2 Day -1 evaluation 
 
Biopsy and placement of catheter(s) 
 
Vital signs and neurologic function per PICU standard  
 
6.7.3 Day 0 Evaluations  

UAB Protocol #:  1472   
Version 04.20.2020 
Page 24 
CT scan to confirm placement of the catheters 
G207 infusion 
Vital signs and neurologic function (Glasgow Coma Scale and neurological exam) 
will be monitored every hour x 6, then every 2 hours overnight for the first 24 hours. 
6.7.4 Day 1 - 4 Evaluations  
Vital signs and neurologic function each day 
Modified Lansky or Karnofsky status determination  
HSV detection Day 1, and Day 3 or 4 (HSV culture saliva, conjunctival secretions; 
HSV PCR saliva, conjunctival secretions, blood) 
CMP, magnesium, phosphorous on Day 2 
CBC with lymphocyte markers on Day 2 
MRI with and without contrast of the brain on Day 3 or 4. This MRI will be the 
first in a series of MRIs, and will be used a baseline for evaluation of potential 
clinical response. Should there be medical indication prior to 72 hours, MRI will 
be performed as deemed necessary by the Principal Investigator or medical 
monitors. 
For patients receiving radiation therapy on Day 1, they will have a CT scan for 
radiation simulation  
6.7.5 Day 7 Evaluations 
Vital signs  
History and Physical including complete neurological status on exam  
Modified Lansky or Karnofsky status determination 
CMP, magnesium, phosphorous 
CBC with lymphocyte markers 
HSV detection (HSV culture saliva, conjunctival secretions; HSV PCR saliva, 
conjunctival secretions, blood) 
6.7.6 Day 14 Evaluations 
Vital signs  
History and Physical including complete neurological status on exam  
Modified Lansky or Karnofsky status determination 
CBC with lymphocyte markers 
HSV detection (HSV culture saliva, conjunctival secretions; HSV PCR saliva, 
conjunctival secretions, blood) 
6.7.7 Day 28 (+/- 7 days) Evaluation 
Vital Signs 
History and Physical including complete neurological status on exam    
CMP, magnesium, phosphorous, CBC with lymphocyte markers 
Modified Lansky or Karnofsky score 
HSV antibody titer 
HSV detection (HSV culture saliva, conjunctival secretions; HSV PCR saliva, 
conjunctival secretions, blood) 
MRI with/without contrast 
6.7.8    Month 3, 5, 7, 9 and 12 (+/- 14 days) Evaluations 
Vital Signs 

UAB Protocol #:  1472   
Version 04.20.2020 
Page 25 
History and Physical including complete neurological status on exam    
CBC with lymphocyte markers 
Modified Lansky or Karnofsky score 
HSV antibody titer by ELISA 
HSV detection (HSV culture saliva, conjunctival secretions; HSV PCR saliva, 
conjunctival secretions, blood) 
MRI with/without contrast of brain  
 
6.7.9 Months 18, 24, and yearly Follow-up 
All surviving study patients will receive follow-up clinic visits at 18 and 24 months to 
include the same evaluations in 6.7.8 and then yearly for up to 15 years after therapy for 
assessment of adverse events/serious adverse events possibly related to G207 even if the 
study is terminated or the patient withdraws from the study. Particular attention will be 
paid to any symptoms (neurological or otherwise) consistent with HSV infection. 
Patients who are unable to follow-up in person will be contacted by telephone on a 
yearly basis to monitor for delayed events. 
6.7.10 Quality of life (optional consent) will be assessed at study enrollment, 1, 3, 5, and 
12 month visits by using the PedsQLTM Brain Tumor Module, WHOQOL Group 
Quality of Life BREF, and the Brief Symptom Inventory 18. 
6.7.11 Blood sample (optional consent). An extra teaspoon of blood will be drawn in a 
lavender top tube during a routine blood draw at screening, day 2, 7, 14, 28 and month 
3, 5, 7, 9, 12, 18, 24, and then yearly thereafter.  
 
7.0 Study Test Article: 
7.1 Investigational Product Designation 
G207 is supplied by Treovir, Inc. in sterile, labeled 1.0 mL cryovials containing 0.12 mL 
of G207 suspended in the storage buffer, D-PBS/10% glycerin. The vials should remain frozen at 
-60C or below until use.  G207 will be stored in the pediatric hematology-oncology pharmacy 
prior to being injected. See appendix C for preparation guidelines. 
7.2 Dose 
A total of 2.4 mL (in 1-4 doses) will be used for treatment. To prepare the dose, the vial 
should be removed from the -60º C freezer and rubbed gently between gloved hands until all the 
ice crystals have melted. The vial should then be placed on ice. It should be thawed completely 
before removing the cap. Care should be taken to ensure that all the liquid is at the bottom of the 
vial before removing the cap to avoid spillage. If it is suspected that the contents are on the side or 
top of the vial, the vial can be tapped gently on a flat surface. The appropriate dose level will be 
prepared according to the dose escalation scheme. The final diluted G207 should be gently 
withdrawn into the syringe for injection. Complete instructions for dose preparation will be 
provided prior to initiation of the clinical study. 
7.3 Precautions in Handling and Disposal 
7.3.1 General Procedures 
Sterile technique and Biosafety Level 2 precautions (gown, gloves, mask) will be 

UAB Protocol #:  1472   
Version 04.20.2020 
Page 26 
rigorously followed while preparing the dose. The dose preparations will take place in a biosafety 
hood. The vial of G207 will be removed from the controlled access freezer and thawed as above 
in section 7.2. It will be allowed to thaw completely prior to removing cap. Care will be taken to 
ensure that all of the liquid is at the bottom of the vial prior to removing the cap and that the cap 
is removed carefully to avoid spilling or contamination.  
7.3.2 Disposal Procedures 
All materials that have been in contact with the G207 herpes virus are considered to be 
infectious biohazards, and must be decontaminated or incinerated prior to disposal. Needles and 
syringes should be placed into a puncture-resistant, leak-proof container containing disinfectant. 
All materials that have been in contact with the vector must be incinerated in an institutionally 
approved biohazard incinerator before disposal 
7.3.3 Investigational Drug Accountability 
  The Investigator must maintain accurate records of dates, quantities, and lots of 
product(s) received, to whom dispensed (subject-by-subject accounting), and accounts of any 
product accidentally destroyed.  The Investigator must retain all unused, partially used or expired 
product until the drug manufacturer has confirmed accountability data. 
At the conclusion of drug administration, all unused and partially used drug supplies 
will be returned to Treovir, Inc., An overall summary of all drug supplies received, unused, 
partially used, wasted, and returned must be prepared at the conclusion of the study. 
8.0   Study Conduct: 
8.1 Clinical Events:  Adverse Medical Experiences and Concurrent Illnesses 
8.1.1 Definitions of Untoward Events Occurring During the Study  
Adverse Experience (AE): An adverse event (AE) is defined as any untoward medical 
occurrence associated with the use of a drug in humans, whether or not considered drug 
related. An AE can be any unfavorable and unintended sign (e.g., abnormal laboratory 
finding), symptom, or disease temporally associated with the use of a drug, without any 
judgment about causality. An AE can arise from any use of the drug and from any route of 
administration, formulation, or dose, including an overdose. An illness or condition present 
at study entry is considered a pre-existing condition and will not be considered an AE 
unless the pre-existing condition worsens during the course of the study. This change may 
be considered an AE. An AE that occurs after signing informed consent but prior to the 
administration of study drug will be considered not related to study treatment. AE’s that 
have a grade increase to 4 or 5 will be considered an SAE and reported as required. All 
AE’s, irrespective of relationship to study drug, which occur or worsen after signing of 
consent form until 30 days after administration of study drug, must be reported and 
documented on the AE Case Report Form (CRF). All medications given for an AE will be 
reported on the Concomitant Medication CRF. Hospitalizations that are expected due to 
the disease and those that are unrelated to the study drug or disease will be reported as AE’s 
unless it meets the requirements for a serious adverse event (SAE). Hospitalizations due to 
merely diagnostic reasons, examinations as a matter of routine or planned surgery and due 
to social indication do not represent a hospitalization in the sense of the term “serious”.  
Laboratory Abnormalities: All abnormal laboratory values must be evaluated according to 

UAB Protocol #:  1472   
Version 04.20.2020 
Page 27 
Common Toxicity Criteria. Clinically significant changes from baseline in hematology, 
serum chemistry, and/or urinalysis values, within or outside of the reference (normal) 
range, are notable and may constitute an adverse event. All laboratory values found to be 
significantly above or below the institutional norm must be repeated and evaluated by the 
Investigator as soon as possible, and documented on the case report form. An abnormal 
clinical laboratory result corresponding to the Common Terminology Criteria for Adverse 
Events (CTCAE) v5.0 Grade 4 is by definition a life threatening experience. 
Serious Adverse Event (SAE): Any clinical event that is fatal or life-threatening, 
permanently disabling, or requires or prolongs hospitalization. Congenital anomalies and 
new occurrences of cancer also will be considered as serious adverse events. 
Expected Adverse Events Associated with G207: G207 caused no dose limiting toxicities 
in adult studies and the adverse events observed following treatment were not thought to 
be attributable to the study drug. Adverse events occurring after the administration of G207 
included the following, which are therefore expected to possibly occur after G207: 
• 
Headache 
• 
Nausea 
• 
Vomiting 
• 
Diarrhea 
• 
Anorexia 
• 
Weakness 
• 
Fatigue 
• 
    Lethargy 
• 
Seizure 
• 
    Abnormal mentation 
• 
Anemia 
• 
Thrombocytopenia 
• 
Leukopenia/neutropenia 
• 
Fever 
• 
Transaminitis 
• 
Skin infection 
• 
Varicella zoster infection 
• 
Pseudoprogression (transient enlargement of tumor on MRI) 
• 
    Hematoma 
Unexpected Event: Any clinical event that is not identified in nature, severity or frequency 
in the risk information included above under expected adverse events. 
Associated with the Use of the Drug: A reasonable possibility exists that the test article 

UAB Protocol #:  1472   
Version 04.20.2020 
Page 28 
may have directly or indirectly caused the clinical event. The Investigator will be unbiased 
in assessing the relationship of the event and test article and discuss the possible relatedness 
to treatment with the Medical Monitor.  Factors which weigh in the clinical assessment of 
causality will be recorded in the medical record by the principal investigator.  The 
following criteria will be used to describe association of AEs and SAEs with G207: 
A.  Definitely Related:  There is a clinically plausible time sequence between the onset 
of the AE and G207 administration and all other potential causes have been ruled 
out. 
B. Probably Related:  There is a clinically plausible time sequence between the onset 
of the AE and G207 administration; the AE is unlikely to be caused by the 
concurrent/underlying illness, other drugs, or procedures; and (if applicable) the 
AE follows a clinically consistent resolution pattern upon withdrawal of G207. 
C. Possibly Related:  There may or may not be a clinically plausible time sequence 
between the onset of the AE and G207 administration and investigational drug as a 
cause cannot be ruled out. 
D. Unlikely Related:  There is probably NOT a clinically plausible time sequence 
between the onset of the AE and G207 administration; the AE is likely to be caused 
by the concurrent/underlying illness, other drugs, or procedures (if applicable) and 
the AE does not follow a clinically consistent resolution pattern of treatment with 
G207. 
E. Not Related:  Another cause of the AE is most plausible; a clinically plausible 
temporal sequence is inconsistent with the onset of the AE and G207 
administration; and/or a causal relationship is considered biologically implausible. 
8.2 Reporting of Clinical Events 
Adverse experiences will be recorded on the AE form. The Investigator will include the 
date of occurrence, the date of cessation (or the fact that it is still continuing), the intensity, and 
the relationship to test article administration, any resulting treatment or change in treatment, and 
the outcome of the event.  
8.3 Reporting of Serious Life-Threatening Adverse Event 
Any serious and unexpected suspected adverse reaction which occurs during the conduct 
of this study, regardless of relationship to test article or procedures, will be reported within 24 
hours to the Medical Monitors and UAB CTMC, and a written report filed within 7 days after the 
event to the Medical Monitors, the Investigator's Institutional Review Board (IRB), the UAB 
CTMC, and the FDA. 
8.4 Declaration of Treatment Failure - Patient Taken Off Treatment or Off Study 
Patients whose tumors show radiographic or clinical evidence of progressive growth will 
be declared Treatment Failures and may be considered for some other available therapy without 
restriction, including standard (re-resection, repeat fractionated radiotherapy, and/or 
chemotherapy) and experimental (biological agents, gene therapy, and novel combinations and 
administration routes of existing agents) interventions.  Patients receiving alternative cancer 
therapies will continue to be followed in this study; details of subsequent therapy, progression, and 
survival will continue to be collected.  Patients (or guardians of patients) who withdraw consent 

UAB Protocol #:  1472   
Version 04.20.2020 
Page 29 
from further participation in this clinical study will be considered off study.  
Off study criteria also includes:  
• Patient determined to be ineligible 
• Patient no longer meets eligibility criteria after enrollment but before therapy  
• Subject death  
8.5 Insurance and Indemnity 
Information on compensation, insurance and indemnity will be supplied to the investigator 
in the clinical agreement. 
8.6 Protocol Deviations 
Except in cases that would commonly be considered medical emergencies, the investigator 
will not deviate from the protocol without prior permission from the oversight committee and the 
IRB. In the event of a medical emergency, these two regulatory boards will be notified as soon as 
possible. All other changes in the study procedures will be implemented as amendments and will 
be approved by the IRB before implementation. 
8.7 Data and Safety Monitoring Plan 
Because this study is a Phase I trial investigating the safety of a newly developed agent 
being administered to pediatric patients for the first time and has a relatively small number of 
patients enrolled at a single institution that will be assuming the full burden of risk, the principal 
investigator, medical monitors, and UAB Clinical Trials Monitoring committee (CTMC) will be 
involved in continuous monitoring of the safety data for all patients that receive the investigational 
drug.  The principal investigator will have direct accountability to the CTMC, and will submit 
monthly, detailed reports to the committee concerning the immediate and long-term follow-up 
safety of all patients that have received the investigational agent. These reports will be reviewed 
by the CTMC on a regularly scheduled basis, with additional reviews being conducted both prior 
to any dose escalation and immediately following any evidence of unacceptable toxicity. 
8.8 Retention of Records 
To comply with FDA regulations, the Investigator must maintain the records of 
investigational drug disposition, subject exclusion logs, signed consent forms, electronic Case 
Report Forms, all correspondence, and supporting documentation for a minimum of 2 years after 
the date on which a US marketing application has been approved for the indication investigated in 
this study or, if no application is to be filed, until 2 years after the investigation is discontinued 
and the FDA/OBA are notified. The Investigator may withdraw from the responsibility to maintain 
records and transfer custody of the records to another person who will accept responsibility for 
them. 
 
9.0 Study Analysis:  
In general, descriptive statistics will be used to summarize the safety and efficacy variables 
collected and the baseline demographic data. Continuous variables will be summarized using 
mean, standard deviation, minimum, median, and maximum. Categorical variables will be 
summarized using frequency counts and percentages. For time-to-event variables, median time-

UAB Protocol #:  1472   
Version 04.20.2020 
Page 30 
to-event, and other percentiles may be presented. Additional exploratory analyses of the data on 
some of the secondary endpoints will be conducted as deemed appropriate. 
9.1 Analysis of Safety 
9.1.1 Safety and Tolerance of G207 Administration (Primary Endpoint #1) 
All subjects who receive G207 will be included in the safety analysis.  Adverse 
events will be described and the frequency of events will be both tabulated overall and by dose 
group. All events with a Grade 3 or above toxicity (where toxicity is defined by the CTCAE v5.0) 
will be summarized separately and tabulated by event and by relationship to G207, both overall 
and by dose group. Laboratory analyses (chemistries, hematology, serological/immunological 
analyses, PCR, cultures, WBC and differential) will consist of measurements of change from 
baseline over time by patient and overall, with plots of actual values compared to normal values 
for patients by dose group. Logarithmic transformations may be applied as necessary. Group 
means and standard errors will be calculated for the various laboratory parameters. Concurrent 
illnesses will be listed and examined as possible confounders in the treatment response 
relationship. Concurrent medications will also be listed, as will previous treatments for malignant 
brain tumors. Effects of concomitant medications and previous treatments for cancer and any 
potential related side effects will be analyzed and discussed. The MTD or maximal planned dose, 
if no dose-limiting toxicity is observed, will be established. 
9.1.2 Immunologic Response to G207 (Secondary Endpoint #1) 
HSV-1 antibody titers will be checked by ELISA on all patients prior to the 
administration of G207 and at Day 28 and Months 3, 5, 7, 9 and 12.  Descriptive statistics of this 
secondary endpoint will be computed. 
9.1.3 Virologic Shedding Following G207 (Secondary Endpoint #2) 
Saliva, blood and conjunctival secretions of all patients will be checked by PCR 
and culture at regular intervals (prior to administration, Day 1, 3 or 4, 7, 14, 28, and Months 3, 5, 
7, 9, 12, 18, 24 and yearly thereafter) for evidence of HSV shedding and/or viremia.  Descriptive 
statistics of this secondary endpoint will be computed.  
9.2 Clinical Response (Secondary Endpoint #3) 
Although not a primary objective of the study, an evaluation of response will be 
performed. Response rates will be calculated in treated patients that are considered evaluable. All 
time-to-event variables (PFS, OS) will be assessed. Descriptive statistics of this secondary 
endpoint will be computed.  
 
9.2.1 Radiographic Response 
Following the treatment, an evaluation of response will be performed.  MRI study 
prior to G207 administration will be considered the baseline. Technical parameters for the baseline 
scan and evaluation scans will be identical (see appendix D). Two-dimensional measurements 
obtained at the baseline scan will be compared with the follow-up MRI scans for assessment of 
response primarily as described in the immunotherapy Response Assessment in Neuro-Oncology 
(iRANO) criteria and summarized below:  
Complete Response (CR): Disappearance of all enhancing disease for ≥ 4 weeks; 

UAB Protocol #:  1472   
Version 04.20.2020 
Page 31 
no new lesions; stable or improved T2/FLAIR; no more than physiological steroids; 
clinically stable or improved.  
Partial response (PR): ≥ 50% decrease in the sum of biperpendicular diameters of 
enhancing disease for ≥4 weeks; no new lesions; stable or improved T2/FLAIR; 
stable or decreased steroid dose; clinically stable or improved.  
Stable Disease (SD): Does not qualify for complete response, partial response, or 
progressive disease; no new lesions; stable or improved T2/FLAIR; stable or 
decreased steroid dose; clinically stable or improved.  
Progressive Disease (PD): ≥ 25% increase in the sum of biperpendicular diameters 
of enhancing disease; or new lesions; or substantial worsened T2/FLAIR; or 
substantial clinical decline. Due to the possibility of pseudoprogression, a well-
known entity seen in oncolytic viral therapy and immunotherapy, confirmation of 
disease progression on follow-up imaging after initial radiographic progression will 
be determined if there is no new or substantially worsened neurological deficits that 
are not due to comorbid events or concurrent medication, and it is 6 months or less 
from receiving G207. During the interval, the patient may be watched or treated 
with bevacizumab and/or dexamethasone at the discretion of the investigators. If 
follow-up imaging confirms disease progression, the date of actual progression will 
be back-dated to the date of initial radiographic progression. The appearance of 
new lesions 6 months or less from the initiation of immunotherapy alone does not 
define progressive disease. When a tumor cannot be classified strictly by iRANO 
criteria, T2/FLAIR abnormality may be used for two-dimensional measurements 
and response may be determined by consensus among the treating physicians.    
The percent of subjects who, at any time point following G207 administration and 
prior to other cancer therapy, demonstrate PD, SD, PR, CR will be summarized. 
Patients' radiographic responses will also be reported by evaluation time points and 
by dosing cohorts.  Longitudinal evaluation of region-of-interest based and 
histogram based analysis of the diffusion parameters (apparent diffusion coefficient 
and mean diffusivity) and perfusion parameters (Ktrans and rCBV) will be performed 
both at the baseline and follow-up MRIs to demonstrate if change of these 
parameters from baseline is related to the infused dose of virus and if the change 
from baseline can predict progression-free and overall survival. Changes in clinical 
disease status and steroid administration will be considered at each time point of 
imaging evaluation.  Measurements will also be analyzed with consideration of any 
anti-tumor cancer therapies and timeframes administered.  
9.2.2 Performance Score  
A Modified Lansky or Karnofsky score will be recorded and measured serially with 
the pre-treatment score.  Time to a Karnofsky score of ≤30 (modified Lansky score of ≤30 in 
children ≤10 years of age) will be explored. Descriptive statistics of this secondary endpoint will 
be computed.  
9.2.3 Progression Free survival  
Time after G207 administration to clinical and radiographic disease progression 
(progression free survival) will be evaluated in all patients receiving G207.  Descriptive statistics 

UAB Protocol #:  1472   
Version 04.20.2020 
Page 32 
of this secondary endpoint will be computed.  
9.2.4 Overall Survival 
The overall survival for each patient receiving G207 will also be reported.  
Descriptive statistics of this secondary endpoint will be computed. 
9.2.5 Quality of Life (optional consent)  
Each patient's self-report (or the caretaker's report, if the patient is <60 months old) 
of quality of life will be measured with the PedsQOL questionnaire at baseline (before 
administration of G207) and at specified times thereafter. The primary caregiver will also complete 
the WHOQOL Group Quality of Life BREF, which measures parent quality of life, and the Brief 
Symptom Inventory 18, which measures distress. The clinical course of the tumor will be taken 
into account in the interpretation of the trends that are found.  Descriptive statistics of this 
secondary endpoint will be computed.   

UAB Protocol #:  1472   
Version 04.20.2020 
Page 33 
References: 
1. 
Markert, JM, Medlock MD, Rabkin SD, et al. Conditionally replicating herpes simplex 
virus mutant, G207 for the treatment of malignant glioma: results of a phase I trial. Gene 
Ther 7:867-74, 2000 
2. 
Markert, JM, Liechty PG, Wang W, et al. Phase Ib trial of mutant herpes simplex virus 
G207 inoculated pre-and post-tumor resection for recurrent GBM. Mol Ther, 17:199-207, 
2009 
3.  
Markert, JM, Razdan SN, Kuo HC, et al. A Phase 1 Trial of Oncolytic HSV-1, G207, 
Given in Combination With Radiation for Recurrent GBM Demonstrates Safety and 
Radiographic Responses. Mol Ther. 22:1048-55, 2014 
4.  
Gatta G, Capocaccia R, Coleman MP, Ries LA, Berrino F.  Childhood cancer survival in 
Europe and the United  States. Cancer. 95:1767-72, 2002 
5. 
Cohen KJ, Pollack IF, Zhou T, et al. Temozolomide in the treatment of high-grade 
gliomas in children: a report from the Children's Oncology Group. Neuro Oncol. 13:317-
23, 2011 
6. 
Gajjar A and Pizer B. Role of high-dose chemotherapy for recurrent medulloblastoma 
and other CNS primitive neuroectodermal tumors. Pediatr Blood Cancer. 54:649-51, 
2010 
7. 
Diller L, Chow EJ, Gurney JG, et al. Chronic disease in the Childhood Cancer Survivor 
Study cohort: a review of published findings. J Clin Oncol. 27:2339-55, 2009 
8.  
Ribi K, Relly C, Landolt MA, Alber FD, Boltshauser E, Grotzer M.A. Outcome of 
medulloblastoma in children: long-term complications and quality of life. 
Neuropediatrics. 36:357-65, 2005 
9. 
Kiltie AE, Lashford LS, Gattamaneni HR. Survival and late effects in medulloblastoma 
patients treated with craniospinal irradiation under three years old. Med Pediatr Oncol. 
28:348-54, 1997 
10. 
Packer RJ. Sutton LN, Atkins TE, et al. A prospective study of cognitive function in 
children receiving whole-brain radiotherapy and chemotherapy: 2-year results. J 
Neurosurg 70:707-13,1989 
11. 
Roizmzn B, Sears AE.  Herpes Simplex Viruses and their Replication.  In Fundamental 
Virology, 3rd ed, pp 1043-1107.  Edited by B.N. Fields, D.M. Knipe & P.M. Howley.  
Philadelphia: Lippincott-Raven, 1996 
12. 
Chou J, Kern ER, Whitley RJ, Roizman B. Mapping of herpes simplex virus-1 
neurovirulence to gamma 134.5, a gene nonessential for growth in culture. Science 
250;1262-6, 1990 
13. 
Chou J, Roizman, B. Herpes simplex virus 1 gamma(1)34.5 gene function, which blocks 
the host response to infection, maps in the homologous domain of the genes expressed 
during growth arrest and DNA damage. Proc Natl Acad Sci U S A. 91:5247-51. 1994 
14. 
Martuza RL, Malick A, Markert JM, Ruffner  KL, Coen DM. Experimental therapy of 
human glioma by means of a genetically engineered virus mutant. Science 252:854-6, 
1991 
15. 
Markert JM, Coen DM, Malick A,  Mineta T, Martuza RL. Expanded spectrum of viral 
therapy in the treatment of nervous system tumors. J Neurosurg 77:590-4, 1992 
16. 
Markert JM, Malick A, Coen DM, Martuza RL. Reduction and elimination of 
encephalitis in an experimental glioma therapy model with attenuated herpes simplex 
mutants that retain susceptibility to acyclovir. Neurosurgery 32:597-603, 1993 

UAB Protocol #:  1472   
Version 04.20.2020 
Page 34 
17. 
Mineta T, Rabkin SD, Martuza RL. Treatment of malignant gliomas using ganciclovir-
hypersensitive, ribonucleotide reductase-deficient herpes simplex viral mutant. Cancer 
Res 54:3963-6, 1994 
18. 
Chambers R. Gillespie GY, Soroceanu L, et al. Comparison of genetically engineered 
herpes simplex viruses for the treatment of brain tumors in a scid mouse model of human 
malignant glioma. Proc Natl Acad Sci U S A. 92:1411-5, 1995 
19. 
Mineta T, Rabkin SD, Yazaki T, Hunter WD, Martuza RL. Attenuated multi-mutated 
herpes simplex virus-1 for the treatment of malignant gliomas. Nat Med 1:938-43, 1995 
20. 
Markert JM, Gillespie GY, Weichselbaum RR, Roizman B, Whitley, R. J. Genetically 
engineered HSV in the treatment of glioma: a review. Rev Med Virol. 10:17-30, 2000 
21. 
Whitley RJ, Alford CA, Hirsch MS, et al. Vidarabine versus acyclovir therapy in herpes 
simplex encephalitis. N Engl J Med. 314:144-9, 1986 
22. 
Goldstein DJ, Weller SK. Herpes simplex virus type 1-induced ribonucleotide reductase 
activity is dispensable for virus growth and DNA synthesis: isolation and characterization 
of an ICP6 lacZ insertion mutant. J Virol 62, 196-205 (1988). 
23.  
Gillory LA, Megison ML, Stewart JE, et al. Preclinical evaluation of engineered 
oncolytic herpes simplex virus for the treatment of neuroblastoma. PLoS One. 8:e77753, 
2013 
24.  
Megison ML, Gillory LA, Stewart JE, et al. Preclinical evaluation of engineered 
oncolytic herpes simplex virus for the treatment of pediatric solid tumors. PLoS One. 
9:e86843, 2014 
25.  
Pressey JG, Haas MC, Pressey CS, Kelly VM, Parker JN, Gillespie GY, Friedman GK.  
CD133 marks a myogenically primitive subpopulation in rhabdomyosarcoma cell lines 
that are relatively chemoresistant but sensitive to mutant HSV. Pediatr Blood Cancer. 
60:45-52, 2013. 
26.  
Friedman GK, Langford C, Coleman J, Cassady K, Parker J, Markert J, Gillespie GY. 
Engineered herpes simplex virus efficiently infects and kills CD133+ glioma cells that 
express CD111. J Neurooncol. 95:199-209. 2009 
27.  
Friedman GK, Kelly VM, Bray A, Cassady KA, Markert JM, Gillespie GY. Clinically-
ready oncolytic engineered herpes simplex viruses kill medulloblastoma neurospheres 
from patient-derived xenolines. Neuro Oncol. 14(Suppl 1):91-92, 2012.    
28.  
Friedman GK, Bharara S, Langford C, Coleman J, Gillespie GY.  Engineered herpes 
simplex virus oncolytic therapy kills both tumor cells and glioma progenitor cells in a 
pediatric high-grade glioma.  Abstracts from the Thirteenth International Symposium on 
Pediatric Neuro-Oncology. Neuro Oncol.  10:508-509, 2008. 
30. 
Friedman GK, Pressey JG, Reddy AT, Markert JM, Gillespie GY.  Herpes simplex virus 
oncolytic therapies for pediatric malignancies.  Mol Ther. 17:1125-35, 2009 
31. 
Andreansky S, Soroceanu L, Flotte ER. Evaluation of genetically engineered herpes 
simplex viruses as oncolytic agents for human malignant brain tumors. Cancer Res 
57:1502-9, 1997 
32. 
Sundaresan P, Hunter WD, Martuza RL, Rabkin SD.  Attenuated replication-competent 
herpes simplex virus 1 mutant G207: safety evaluation in mice.  J Virol 74:3832-3841, 
2000 
33.  
Hunter, W.D. Martuza RL, Feigenbaum F, et al.  Attenuated, Replication-Competent 
Herpes Simplex Virus Type 1 Mutant G207: Safety Evaluation of Intracerebral Injection 
in Nonhuman Primates.  J Virol, 73:6319-6326, 1999 

UAB Protocol #:  1472   
Version 04.20.2020 
Page 35 
34.  
Advani S., Sibley G, Hallahan DE, Roizman B, Weichselbaum RR. Enhancement of 
replication of Genetically Engineered Herpes Simplex Virus by ionizing radiation: a new 
paradigm for destruction of intractable tumors. Gene Ther 5: 160-165, 1998 
35. 
Bradley JD, Kataoka Y, Advani S, et al. Ionizing radiation improves survival in mice 
bearing intracranial high-grade gliomas injected with genetically modified herpes 
simplex virus. Clin Cancer Res 5: 1517-1522, 1999 
36.  
Stanziale SF, Petrowsky H, Joe JK, Roberts GD, Zager JS, Gusani NJ, Ben-Porat L, 
Gonen M, Fong Y. Ionizing radiation potentiates the antitumor efficacy of oncolytic 
herpes simplex virus G207 by upregulating ribonucleotide reductase. Surgery. 132:353-9, 
2002 
37. 
Xu F, Lee FK, Morrow RA, Sternberg MR, Luther KE, Dubin G et al. Seroprevalence of 
herpes simplex virus type 1 in children in the United States. J Pediatr 151:374–377, 2007 
38. 
Whitley R.J., Kimberlin D.W. and Roizman B.  Herpes Simplex Virus. Clin Infect Dis 
26:541-553, 1998 
39. 
Fontanilla HP, Pinnix CC, Ketonen LM, Woo SY, Vats TS, Rytting ME, Wolff JE, 
Mahajan A.Palliative reirradiation for progressive diffuse intrinsic pontine glioma. Am J 
Clin Oncol 35:51-57, 2012 
40. 
Nieder C, Astner ST, Mehta MP, Grosu AL, Molls M. Improvement, clinical course, and 
quality of life after palliative radiotherapy for recurrent glioblastoma. Am J Clin Oncol 
31:300-305, 2008 
41. 
Bauman GS, Sneed PK, Wara WM, Stalpers LJ, Chang SM, McDermott MW, Gutin PH, 
Larson DA. Reirradiation of primary CNS tumors. Int J Radiat Oncol Biol Phys 36:433-
441, 1996. 
42. 
Kimberlin DW, Whitley RJ. Viral infections of the newborn infant.  In:  Rudolph's 
Pediatrics, 22nd edition.  Rudolph CD, Rudolph AM, Hostetter MK, Lister G, Siegel NJ 
(eds). McGraw Hill Medical, New York, March, 2011. 
43. 
G, Mescheder A, Jarnagin W, Kemeny N. A herpes oncolytic virus can be delivered via 
the vasculature to produce biologic changes in human colorectal cancer. Mol Ther.  
17:389-94, 2009 
44. 
Carceller F, Fowkes LA, Khabra K, Moreno L, Saran F, Burford A, Mackay A, Jones 
DT, Hovestadt V, Marshall LV, Vaidya S, Mandeville H, Jerome N, Bridges LR, Laxton 
R, Al-Sarraj S, Pfister SM, Leach MO, Pearson AD, Jones C, Koh DM, Zacharoulis S. 
Pseudoprogression in children, adolescents and young adults with non-brainstem high 
grade glioma and diffuse intrinsic pontine glioma. J Neurooncol 129:109-21, 2016. 
45. 
Zamora C, Lopez M, Cunningham F, Collichio F, Castillo M. Imaging Manifestations of 
Pseudoprogression in Metastatic Melanoma Nodes Injected with Talimogene 
Laherparepvec: Initial Experience. AJNR Am J Neuroradiol. 2017 Apr 20.  
46.  
Miyatake S, Furuse M, Kawabata S, Maruyama T, Kumabe T, Kuroiwa T, Ono K. 
Bevacizumab treatment of symptomatic pseudoprogression after boron neutron capture 
therapy for recurrent malignant gliomas. Report of 2 cases. Neuro Oncol 15:650-655, 
2013. 
47. 
Levin VA, Bidaut L, Hou P, Kumar AJ, Wefel JS, Bekele BN, Grewal J, Prabhu S, 
Loghin M, Gilbert MR, Jackson EF. Randomized double-blind placebo-controlled trial of 
bevacizumab therapy for radiation necrosis of the central nervous system. Int J Radiat 
Oncol Biol Phys 79:1487-95, 2011. 
48.  
Liu AK, Macy ME, Foreman NK. Bevacizumab as therapy for radiation necrosis in four 

UAB Protocol #:  1472   
Version 04.20.2020 
Page 36 
children with pontine gliomas. Int J Radiat Oncol Biol Phys 75:1148-54, 2009.48.  
49. 
Foster KA, Ares WJ, Pollack IF, Jakacki RI. Bevacizumab for symptomatic radiation-
induced tumor enlargement in pediatric low grade gliomas. Pediatr Blood Cancer 
62:240-245, 2015. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

UAB Protocol #:  1472   
Version 04.20.2020 
Page 37 
APPENDICES 
 
 
 
Appendix A 
 
 
Patient Study Schedule 
  
Appendix B 
 
 
 Modified Lansky and Karnofsky Status Determination 
 
Appendix C 
            Preparation of G207 
 
Appendix D 
 
 
MRI Sequences 
 

UAB Protocol #:  1472   
 
 
 
 
 
 
 
 
    Page 
             
 
i 
 APPENDIX A 
Patient Study Schedule 
 
 
Pre Day 
-1 
Day 
0 
Day 
1 
Day 
2 
Day 
3or 4 
Day 
7 
Day 
14 
Day 
28 
Month 
3 
Month 
5 
Month 
7 
Month 
9 
Month 12, 
18, 24 †‡ 
History and Physical 
X 
 
 
 
 
 
X 
X 
X 
X 
X 
X 
X 
X 
Complete metabolic panel, magnesium and phosphorous X 
 
 
 
X 
 
X 
 
X 
 
 
 
 
 
Complete blood count with differential and platelets 
including lymphocyte markers 
X 
 
 
 
X 
 
X 
X 
X 
X 
X 
X 
X 
X 
Cystatin C 
X%  
 
 
 
 
 
 
 
 
 
 
 
 
HIV Serology 
X 
 
 
 
 
 
 
 
 
 
 
 
 
 
HSV Antibody Titer 
X 
 
 
 
 
 
 
 
X 
X 
X 
X 
X 
X 
HSV Detection (culture and PCR for Saliva and 
conjunctival secretions, and PCR for Blood)** 
X 
 
 
X 
 
X 
X 
X 
X 
X 
X 
X 
X 
X 
Serum Pregnancy for adolescent female 
X 
 
 
 
 
 
 
 
 
 
 
 
 
 
CT Scan 
 
 
X 
X# 
 
 
 
 
 
 
 
 
 
 
Biopsy and placement of catheter(s) 
 
X 
 
 
 
 
 
 
 
 
 
 
 
 
Dosing 
 
 
X 
 
 
 
 
 
 
 
 
 
 
 
Radiation 
 
 
 
X& 
 
 
 
 
 
 
 
 
 
 
MRI 
X*  
 
 
 
X 
 
 
X 
X 
X 
X 
X 
X 
UA 
X 
 
 
 
 
 
 
 
 
 
 
 
 
 
PT/PTT 
X 
 
 
 
 
 
 
 
 
 
 
 
 
 
Neurological Status on Exam 
X 
 
X§ 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
Performance Score 
X 
 
 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
Quality of Life Evaluation*** 
X 
 
 
 
 
 
 
 
X 
X 
X 
 
 
X 
Vital Signs 
X 
 
X§ 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
Blood sample*** 
X 
 
 
 
X 
 
X 
X 
X 
X 
X 
X 
X 
X 
 
* 
Must be within 14 days of scheduled treatment. 
**   Additional samples for shedding analysis should be taken when clinical signs warrant (i.e. if patients show signs of herpes virus infection due to reactivation) 
*** Optional consent. Quality of life evaluation will be performed at screening, 1, 3, 5, and 12 months. 
%     Only for patients with elevated creatinine level on complete metabolic panel 
#      Only for patients who receive radiation therapy. Patients may get simulation CT scan at screening or Day 1. 
§ 
Frequency post-operatively defined by institutional standards and medical need. 
† 
After the 24 month visit, studies will be performed yearly thereafter, as patient's health permits. 
‡ 
All subjects will continue to receive yearly follow-up by clinic visits (or telephone call for those who cannot be seen in person) for assessment of adverse events / serious adverse events 
that might be related to G207 for up to 15 years after treatment with G207. Particular attention will be paid to any symptoms (neurological or otherwise) consistent with HSV infection. 
&     Only for patients in dose level 3 and 4 

UAB Protocol #:  1472   
 
 
 
 
 
 
 
 
    Page 
             
 
ii 
 APPENDIX B 
 
The Modified Lansky Performance Scale (Patients < 10 year) 
 
MODIFIED LANSKY PERFORMANCE SCALE 
 
 
NORMAL RANGE 
 
 
100 
Fully active. 
90 
Minor restriction in physically strenuous play. 
80 
Restricted in strenuous play, tires more easily, otherwise active. 
 
 
MILD-TO-MODERATE RESTRICTION 
 
 
70 
Both greater restriction of, and less time spent, in active play. 
60 
Ambulatory up to 50% of the time, limited active play with 
assistance and supervision. 
50 
Considerable assistance required for any active play; fully able to 
engage in quiet play. 
 
 
MODERATE-TO-SEVERE 
 
 
40 
Able to initiate quiet activities 
30 
Needs considerable assistance for quiet activity. 
20 
Limited to very passive activity initiated by other (e.g., television) 
10 
Completely disabled, not even passive play 
0 
Unresponsive, comatose 
 
 
 
The Karnofsky Performance Status Scale (Patients ≥ 10 year) 
 
 
100 
Normal, no complaints, no evidence of disease 
 
90 Able to carry on normal activity; some minor symptoms 
 
80 Normal activity with some effort; some symptoms 
 
70 Care for self; unable to carry on normal activities 
 
60 Requires occasional assistance; cares for most needs 
 
50 Requires considerable assistance and frequent care 
 
40 Disabled; requires special care and assistance 
 
30 Severely disabled; hospitalized, death not imminent 
 
20 Very sick; active support treatment needed 
 
10 Moribund; fatal processes are rapidly progressing 
 
 
 
 

UAB Protocol #:  1472   
 
 
 
 
 
 
 
 
    Page 
             
 
iii 
Appendix C 
Preparation of G207 dilutions will take place in the hospital pharmacy. 
G207 should be prepared for administration following Biosafety Level 2 Guidelines 
using a laminar flow biological safety cabinet, hood, gloves, safety glasses and gown. 
MATERIALS NEEDED FOR PREPARATION OF G207 DOSE FOR SUBJECT 
ADMINISTRATION  
1. 70% Isopropanol solution  
2. MetriSpray, Cavicide or equivalent disinfectant. 
3. U-100 Micro-fine IV insulin syringe with fixed 28G 1cm (or 1/2 inch) needle for 
virus delivery (total of 6 syringes needed) 
4. Tuberculin syringe and 18-23 G needle  
5. Sterile Vector Diluent (0.9% sodium chloride, USP, preservative-free for 
injection) cooled to 4°C.   
6. Sterile Gloves 
7. Alcohol Swabs/Wipes 
8. Kim-wipes 
 
EQUIPMENT NEEDED FOR PREPARATION OF G207 DOSE FOR SUBJECT 
ADMINISTRATION 
1. Laminar Flow Biological Safety Cabinet (LFBSC) 
2. Rack for vector G207 Stock Vials 
3. Refrigerator 
4. Wet ice or coolant 
 
METHOD FOR PREPARATION OF G207 DILUTION FOR SUBJECT 
ADMINISTRATION 
1. Remove all items from the LFBSC, wipe down work surfaces with MetriSpray, 
Cavicide or equivalent disinfectant, followed by 70% isopropanol, allow blower 
to run for 30 minutes prior to using.   
2. Cool virus diluent (sterile preservative-free 10% Glycerol in Phosphate Buffered 
Saline, pH 7.0-7.4, USP (Alanza)) to approximately 4°C in a refrigerator or on 
ice. 
3. Thaw the appropriate number of vector stock G207 vial(s) based on dosage 
required by rubbing gently between gloved hands. Continue until the last ice 
crystals have melted and then place vials on ice. Note the time that the contents 
have completely thawed. Do not allow the vials to warm.  
 
 

UAB Protocol #:  1472   
 
 
 
 
 
 
 
 
    Page 
             
 
iv 
4. Wipe stock G207 vials dry with Kim-Wipes.  Gently mix contents of stock G207 
vials.  
5. Wipe stock G207 vials with alcohol swab and place in a vial rack in the LFBSC to 
dry. 
6. Dose Preparation Guide 
6.1 
Draw up the required amount of sterile preservative-free 10% Glycerol in 
Phosphate Buffered Saline, pH 7.0-7.4, USP for injection (vector diluent)   
6.2 
Remove the required volume of stock G207 from the cryovials. Add stock 
G207 to the receptacle/vehicle containing the required diluent 
6.3 
Gently invert end over end at least 5 times to mix contents 
7. Label administration syringe(s) appropriately and load 1 ml diluted G207 into 
each syringe.   
8. Place syringe(s) in sterile syringe holder. 
9. Transport syringe container immediately to patient’s room for administration. 
Syringes will be placed in individual syringe pumps. Syringes must be kept at 
room temperature at all times and infusions completed within 8 hours of thawing 
the vector. Infusion rates for each individual catheter will be dictated by the 
number of catheters as follows: 
400 microliters per hour/(number of active catheters). 
10.  Start and stop time of G207 injection will be documented. 
11.  All reactions or complications encountered during the administration of G207 
should be documented.  
12. All remaining biological material must be chemically disinfected or autoclaved.  
All instruments coming in contact with G207 must be autoclaved.  All other items 
coming in contact with G207 must be incinerated or autoclaved.  
13. Waste Disposal responsibility must be managed according to the institutional SOP 
on disposal of hazardous waste.   
 
 
 
 
 
 
 
 
 
 

UAB Protocol #:  1472   
 
 
 
 
 
 
 
 
    Page 
             
 
v 
Appendix D 
 
All MRI will be performed on a 3T MRI scanner.  The MRI schedule will be: baseline 
(prior to virus injection), Day 3 or 4, Day 28, month 3, 5, 7, 9, 12, 18, 24, and then yearly 
thereafter.  Unscheduled MRI scans may be done if needed to evaluate post-
administration neurological decline.  Sequences needed for the biopsy and resection will 
be determined by the operating neurosurgeon. 
 
SAG T1 
FOV           
     FH (mm) = 230;  
     AP (mm) = 230; 
     RL (mm) = 154; 
Echoes = 1; 
     partial echo = "no"; 
TE ="user defined"; 
     (ms) =10; 
Flip angle (deg) = 70; 
TR = "range"; 
   minimum (ms) = 600; 
   maximum (ms) = 700; 
Total scan duration = "04:09.6"; 
SAR / head = "< 99 %"; 
Whole body / level = "< 0.2 W/kg / normal"; 
 
Ax T1 
FOV           
AP (mm) = 230; 
      RL (mm) = 183.28125; 
      FH (mm) =141.5; 
Slice thickness (mm) = 5; 
TE ="user defined"; 
     (ms) = 10; 
Flip angle (deg) = 70; 
TR = "range"; 
    minimum (ms) = 600; 
    maximum (ms) = 700; 
Total scan duration = "03:19.2"; 
SAR / head = "< 62 %"; 
Whole body / level = "< 0.1 W/kg / normal"; 
 
Ax T2 
FOV           
AP (mm) = 230; 
      RL (mm) = 182.954544; 
      FH (mm) = 141.5; 

UAB Protocol #:  1472   
 
 
 
 
 
 
 
 
    Page 
             
 
vi 
Slice thickness (mm) = 5; 
Reconstruction matrix = 512; 
TE = "user defined" 
     (ms) =125; 
angle (deg) = 120; 
echo enhancement = "no"; 
bright fat reduction = "no"; 
TR = "user defined"; 
     (ms) = 11000; 
Fast Imaging mode = "TSE"; 
shot mode = "multishot"; 
TSE factor = 31; 
SAR / head = "< 33 %"; 
Total scan duration = "04:36.0"; 
Whole body / level = "< 0.1 W/kg / normal"; 
 
AX FLAIR 
FOV           
     AP (mm) = 230; 
     RL (mm) = 182.954544; 
     FH (mm) = 141.5; 
slices = 22; 
slice gap = "user defined";  
gap (mm) = 
1.5; 
Fast Imaging mode = "TSE"; 
shot mode = "multishot"; 
TSE factor = 31; 
TE = "user defined"; 
      (ms) = 125; 
Refocusing control = "yes"; 
angle (deg) = 120; 
echo enhancement = "no"; 
bright fat reduction = "no"; 
TR = "user defined"; 
     (ms) =11000; 
Total scan duration = "03:51.0"; 
SAR / head = "< 33 %"; 
Whole body / level = "< 0.1 W/kg / normal"; 
 
Ax DWI 
FOV           
      RL (mm) = 230; 
      AP (mm) = 230; 
      FH (mm) = 149; 
Slice thickness (mm) = 4; 
 

UAB Protocol #:  1472   
 
 
 
 
 
 
 
 
    Page 
             
 
vii 
Fast Imaging mode = "EPI"; 
shot mode = "single-shot" 
Echoes = 1; 
TE = "shortest"; 
Flip angle (deg) = 90; 
TR = "shortest"; 
Diffusion mode = "DWI"; 
    nr of b-factors = 2; 
    b-factor order = "ascending"; 
    max b-factor = 1000; 
    average high b = "yes"; 
Total scan duration = "00:37.9"; 
SAR / head = "<  35 %"; 
Whole body / level =  
"< 0.1 W/kg / normal"; 
 
VENBOLD 
FOV           
     AP (mm) = 200; 
     RL (mm) = 200; 
     FH (mm) = 125; 
Reconstruction matrix = 512; 
Scan mode = "3D"; 
TE = "shortest"; 
Flip angle (deg) = 10; 
TR = "shortest"; 
Total scan duration = "05:46.8"; 
SAR / head = "< 4 %"; 
Whole body / level = "0.0 W/kg / normal"; 
 
T1 mapping (2, 10, 15, 20, 30degrees) 
FOV          
     AP (mm) = 256; 
     RL (mm) = 168; 
     FH (mm) = 80; 
TE = "user defined" 
    (ms) = 2.48000002; 
Flip angle (deg) = 2, 10, 15, 20, 30; 
TR = "user defined"; 
    (ms) = 4.88000011; 
Total scan duration = "00:11.5"; "00:05.7"; "00:11.5"; "00:11.5"; "00:11.5"; 
SAR / head = "< 1 %"; 
Whole body / level = "0.0 W/kg / normal"; 
 
DCE perfusion MRI 
FOV         
     AP (mm) = 256; 

UAB Protocol #:  1472   
 
 
 
 
 
 
 
 
    Page 
             
 
viii 
     RL (mm) = 168; 
     FH (mm) = 80; 
Echoes = 1; 
    partial echo = "no"; 
    shifted echo = "no"; 
TE = "user defined"; 
    (ms) = 2.48000002; 
Flip angle (deg) = 20; 
TR = "user defined"; 
    (ms) = 4.88000011; 
Dynamic study = "individual"; 
    dyn scans = 60; 
    dyn scan times = "shortest"; 
    FOV time mode = "default"; 
Total scan duration = "05:43.2"; 
SAR / head = "< 60 %"; 
Whole body / level = "< 0.1 W/kg / normal"; 
 
SAG T1 THRIVE 
Coil selection = "SENSE-Head-8"; 
FOV           
     FH (mm) = 250; 
     AP (mm) = 250; 
     RL (mm) = 166.200012; 
Echoes = 1; 
    partial echo = "no"; 
    shifted echo = "no"; 
TE = "shortest"; 
Flip angle (deg) = 10; 
TR = "shortest"; 
Total scan duration = "04:58.6"; 
SAR / head = "< 21%"; 
Whole body / level ="0.0 W/kg / normal"; 
 
DSC PERFUSION 
FOV           
     RL (mm) = 224; 
     AP (mm) = 224; 
     FH (mm) = 140; 
Voxel size   RL (mm) = 2.32999992; 
                   AP (mm) = 2.32999992; 
Slice thickness (mm) = 4; 
Recon voxel size (mm) = 1.75; 
Fold-over suppression = "no"; 
 
Reconstruction matrix = 128; 

UAB Protocol #:  1472   
 
 
 
 
 
 
 
 
    Page 
             
 
ix 
    slice gap = "user defined"; 
          gap (mm) = 0; 
    slice orientation = "transverse"; 
    fold-over direction = "AP"; 
    fat shift direction = "P"; 
TE = "user defined"; 
     (ms) = 20; 
Flip angle (deg) = 60; 
TR = "shortest"; 
Dynamic study = "individual"; 
    dyn scans = 60; 
    dyn scan times = "shortest"; 
Act. TR/TE (ms) = "2202 / 40"; 
Dyn. scan time = "00:02.2"; 
SAR / head = "< 27 %"; 
Whole body / level = "< 0.1 W/kg / normal"; 
 
Ax T1+C 
FOV           
     RL (mm) = 224; 
     AP (mm) = 224; 
     FH (mm) = 140; 
Echoes = 1; 
    partial echo ="no"; 
TE = "user defined"; 
    (ms) = 12; 
Flip angle (deg) = 70; 
TR = "range"; 
    minimum (ms) = 400; 
    maximum (ms) = 750; 
Total scan duration = "04:08.3"; 
SAR / head = "< 100 %"; 
Whole body / level = "< 0.2 W/kg / normal";